{"gene":"CALM1","run_date":"2026-04-28T17:28:52","timeline":{"discoveries":[{"year":1992,"finding":"Crystal structure of Ca2+-bound calmodulin complexed with a peptide analog of the smooth muscle myosin light chain kinase (MLCK) CaM-binding region at 2.4 Å resolution revealed that CaM forms a compact ellipsoidal tunnel that engulfs the helical target peptide; the central helix of CaM unwinds and expands into a bend between residues 73–77, allowing both hydrophobic domains to merge into a single area surrounding the peptide, with ~185 contacts formed. This established the structural basis of CaM target-peptide recognition.","method":"X-ray crystallography (2.4 Å resolution) of Ca2+/CaM–MLCK peptide complex","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 — high-resolution crystal structure with detailed structural validation; foundational paper with ~950 citations","pmids":["1519061"],"is_preprint":false},{"year":1996,"finding":"Ca2+-dependent binding of calmodulin to the NR1 subunit of NMDA receptors causes a ~4-fold reduction in NMDA channel open probability, establishing CaM as a direct negative regulator of NMDA receptor activity through a Ca2+-dependent feedback mechanism.","method":"Protein purification, in vitro binding assay, co-immunoprecipitation from brain, patch-clamp electrophysiology of homomeric NR1 and heteromeric NR1/NR2 complexes","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1–2 — direct in vitro binding plus electrophysiological functional readout, replicated in brain tissue and recombinant systems; ~465 citations","pmids":["8625412"],"is_preprint":false},{"year":1997,"finding":"Calmodulin binds to the CaM-binding domain of SK (small-conductance Ca2+-activated K+) channel α-subunits constitutively; upon Ca2+ binding exclusively to the N-lobe EF hands of CaM, channel opening is triggered. The interaction is obligatory for channel gating, placing CaM as an intrinsic subunit of SK channels.","method":"Biochemical binding assays; later (2001) crystal structure at 1.60 Å of CaMBD/Ca2+/CaM showing CaM wrapping around three α-helices from a dimeric CaMBD","journal":"Nature (structure paper 2001)","confidence":"High","confidence_rationale":"Tier 1 — 1.60 Å crystal structure plus biochemical data; ~500 citations","pmids":["11323678"],"is_preprint":false},{"year":1997,"finding":"α-Actinin-2 and calmodulin compete for binding to the cytoplasmic tail of the NR1 subunit of NMDA receptors in a Ca2+-dependent manner: Ca2+/calmodulin directly antagonizes NR1–α-actinin binding, suggesting a mechanism by which Ca2+ entry through NMDA receptors can displace cytoskeletal anchoring and regulate receptor localization and activity.","method":"Yeast two-hybrid, co-immunoprecipitation from rat brain, in vitro competition binding assay","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP from brain plus in vitro competition; ~505 citations","pmids":["9009191"],"is_preprint":false},{"year":1997,"finding":"Genetically encoded FRET-based Ca2+ indicators ('cameleons') were constructed using tandem fusions of cyan-GFP, calmodulin, the CaM-binding peptide M13, and yellow-GFP. Ca2+ binding causes CaM to wrap around M13, increasing FRET between flanking GFPs, enabling real-time measurement of free Ca2+ in cytosol, nucleus, and ER of live cells. CaM mutations were used to tune Ca2+ affinity over the range 10⁻⁸–10⁻² M.","method":"Genetic engineering, FRET imaging in live HeLa cells, calmodulin mutagenesis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — reconstitution and mutagenesis with functional validation in live cells; ~2324 citations","pmids":["9278050"],"is_preprint":false},{"year":2001,"finding":"Calmodulin binding to the CaM-binding domain of eNOS is regulated by phosphorylation: constitutive phosphorylation of Thr495 (by PKC) reduces CaM binding, while agonist-induced dephosphorylation of Thr495 by PP1 promotes CaM association and enhances eNOS activity. Mutation of Thr495 to Ala increased CaM binding in unstimulated cells, while Asp495 abolished CaM binding, confirming phosphorylation as the molecular switch controlling Ca2+/CaM-dependent eNOS activation.","method":"Co-immunoprecipitation, site-directed mutagenesis, CaM binding assay, pharmacological inhibitors (Ro 31-8220, calyculin A, KN-93) in porcine aortic endothelial cells","journal":"Circulation Research","confidence":"High","confidence_rationale":"Tier 1–2 — mutagenesis plus co-IP plus pharmacological inhibition with multiple orthogonal methods; ~618 citations","pmids":["11397791"],"is_preprint":false},{"year":1993,"finding":"Chromosomal localization of the three bona fide human calmodulin genes: CALM1 maps to chromosome 14q24–q31, CALM2 to 2p21.1–p21.3, and CALM3 to 19q13.2–q13.3, establishing that these identical-protein-encoding genes are dispersed throughout the genome.","method":"PCR-based amplification from human-hamster somatic cell hybrids; in situ hybridization on human lymphocyte metaphase spreads","journal":"Genomics","confidence":"High","confidence_rationale":"Tier 2 — two orthogonal mapping methods; replicated in multiple studies; ~80 citations","pmids":["8314583"],"is_preprint":false},{"year":1994,"finding":"The human CALM1 gene contains six exons spanning ~10 kb of genomic DNA with a cluster of transcription-start sites 200 bp upstream of the ATG codon. Expression is ubiquitous but differential: a 1.7 kb mRNA is uniformly present while a 4.2 kb mRNA is enriched in brain and skeletal muscle. Two intronless, non-functional pseudogenes (CALM1P1, CALM1P2) were characterized.","method":"Genomic library screening, PCR, Northern blotting, sequencing of human CALM1 gene and flanking regions","journal":"European Journal of Biochemistry","confidence":"High","confidence_rationale":"Tier 2 — direct experimental characterization of gene structure and expression; ~32 citations","pmids":["7925473"],"is_preprint":false},{"year":1998,"finding":"Comparison of transcriptional activity of CALM1, CALM2, and CALM3 in proliferating human teratoma cells revealed that CALM3 is at least 5-fold more actively transcribed than CALM1 or CALM2. The 5' untranslated regions of each CALM gene are necessary to recover full promoter activity in transfection assays, indicating post-transcriptional regulation of calmodulin levels.","method":"Nuclear run-on transcription assay, Northern blotting for mRNA abundance, luciferase reporter transfection with CALM promoter constructs ± 5'UTR in teratoma cells","journal":"Cell Calcium","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal methods (run-on, mRNA quantification, reporter assays) in a single study","pmids":["9681195"],"is_preprint":false},{"year":2005,"finding":"A functional SNP (−16C>T) in the core promoter of CALM1 decreases CALM1 transcription in vitro and in vivo. Inhibition of calmodulin in chondrogenic cells reduced expression of major cartilage matrix genes Col2a1 and Agc1, implicating the CALM1-mediated signaling pathway in chondrocyte differentiation and cartilage matrix production.","method":"Case-control association study; luciferase reporter assay for promoter activity in vitro; in vivo allele-specific transcription analysis; pharmacological calmodulin inhibition in chondrogenic cells with RT-PCR for Col2a1 and Agc1","journal":"Human Molecular Genetics","confidence":"Medium","confidence_rationale":"Tier 2 — reporter assay plus pharmacological inhibition with downstream gene readout; single lab, moderate mechanistic depth","pmids":["15746150"],"is_preprint":false},{"year":2013,"finding":"A missense mutation p.F90L in CALM1 encoding calmodulin was identified in a family with idiopathic ventricular fibrillation (IVF). The F90 residue is a highly conserved residue that mediates the direct interaction of CaM with target peptides, establishing that disruption of CaM–target interactions can cause life-threatening arrhythmia.","method":"Exome sequencing of affected family members; pedigree analysis; conservation analysis of F90 position","journal":"Journal of the American College of Cardiology","confidence":"Medium","confidence_rationale":"Tier 3 — genetic identification with mechanistic inference from prior structural data; no direct functional reconstitution in this paper","pmids":["24076290"],"is_preprint":false},{"year":2014,"finding":"RNAi-mediated knockdown of Calm1 (but not Calm2 or Calm3) in mouse precerebellar neurons caused defective tangential and radial migration, with neurons failing to reach target positions in the hindbrain. This established a gene-specific requirement for CALM1 in neuronal migration that cannot be compensated by the other calmodulin-encoding genes.","method":"Acute in vivo RNAi knockdown of individual Calm genes (shRNA), histological analysis of precerebellar neuron migration in mouse hindbrain","journal":"Development","confidence":"Medium","confidence_rationale":"Tier 2–3 — KD with specific phenotypic readout in vivo; gene-specific effect validated by testing all three paralogs; single lab","pmids":["25519244"],"is_preprint":false},{"year":2015,"finding":"FMRP (Fmr1-encoded protein) associates with miR-181d, Map1b mRNA, and Calm1 mRNA in axons. FMRP mediates axonal delivery of miR-181d, which locally represses translation of Calm1 (and Map1b) in sensory neuron axons, negatively regulating axon elongation. NGF stimulation releases Calm1 mRNA from FMRP/miR-181d-repressing granules, promoting local calmodulin synthesis and axon elongation.","method":"Co-immunoprecipitation of FMRP with miR-181d/Map1b/Calm1; FMRP KO (Fmr1^I304N) and knockdown; axonal fractionation with protein quantification; miR-181d overexpression; NGF stimulation assays in primary sensory neurons","journal":"Cell Reports","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP, KO, and functional elongation assays with multiple orthogonal approaches; single lab","pmids":["26711345"],"is_preprint":false},{"year":2016,"finding":"CALM1 (and CALM2/3) variants causing LQTS reduce CaM affinity for Ca2+ and cause a functionally dominant loss of Ca2+-dependent inactivation (CDI) of the cardiac L-type calcium channel CaV1.2. The novel E141G-CaM variant showed an 11-fold reduction in Ca2+ binding affinity and dominant loss of CaV1.2 CDI, mild NaV1.5 late current accentuation, but no effect on RyR2-mediated Ca2+ release.","method":"Whole-exome sequencing; Ca2+ binding affinity measurements; patch-clamp electrophysiology of CaV1.2, NaV1.5 in heterologous expression; intracellular Ca2+ release assay for RyR2","journal":"Circulation: Cardiovascular Genetics","confidence":"High","confidence_rationale":"Tier 1–2 — biochemical Ca2+ affinity measurement plus electrophysiological characterization of multiple ion channels; multiple methods in one study","pmids":["26969752"],"is_preprint":false},{"year":2017,"finding":"The CALM1-F142L mutation in patient-derived iPSC-CMs causes prolonged repolarization with altered rate-dependency, severe impairment of Ca2+-dependent inactivation (CDI) of ICaL (increased inward current during plateau), and failure of repolarization adaptation at high pacing rates. These effects were reversed by verapamil (ICaL blocker). The mutation did not affect IKs, INaL, or intracellular Ca2+ store stability, placing the primary arrhythmogenic defect specifically at CaV1.2 CDI.","method":"iPSC-CM generation from CALM1-F142L patient; dynamic clamp (simulated IK1); patch-clamp for ICaL CDI, IKs, INaL, If; intracellular Ca2+ imaging; action potential modeling; pharmacological rescue with verapamil","journal":"Cardiovascular Research","confidence":"High","confidence_rationale":"Tier 1–2 — human patient iPSC-CMs with multiple orthogonal electrophysiological methods, pharmacological rescue, and computational modeling","pmids":["28158429"],"is_preprint":false},{"year":2020,"finding":"Heterozygous Calm1-N98S knock-in mice exhibit sinus bradycardia, QTc prolongation, QRS widening, and catecholaminergic bidirectional ventricular tachycardia. β-Adrenergic stimulation increased peak ICaL density, slowed ICaL inactivation, left-shifted ICaL activation, and increased late ICaL significantly more in mutant than wild-type ventricular myocytes. Both reentry and focal mechanisms (EADs in His-Purkinje fibers, DADs in ventricular myocytes) contribute to arrhythmogenesis, establishing β-adrenergically induced ICaL dysregulation as the primary mechanism of the long-QT phenotype.","method":"CRISPR/Cas9 knock-in mouse generation; ECG monitoring; optical voltage mapping; patch-clamp (ICaL, action potentials); fluorescence Ca2+ imaging; microelectrode recording of His-Purkinje fibers; pharmacological β-blocker/agonist treatment","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 1–2 — two independent knock-in lines, multiple orthogonal electrophysiological methods, optical mapping, and pharmacological rescue; strong mechanistic evidence","pmids":["32929985"],"is_preprint":false},{"year":2024,"finding":"A suppression-and-replacement (SupRep) gene therapy construct containing shRNAs targeting CALM1, CALM2, and CALM3 plus a shRNA-immune CALM1 cDNA shortened pathologically prolonged APD90 in CALM1-F142L, CALM2-D130G, and CALM3-D130G iPSC-CMs, demonstrating that a single construct can treat all calmodulinopathy variants regardless of which of the three CALM genes is mutated.","method":"shRNA knockdown efficiency testing in TSA201 cells; lentiviral transfection of SupRep construct into patient-derived iPSC-CMs; voltage-sensing dye measurement of APD90","journal":"Circulation: Arrhythmia and Electrophysiology","confidence":"Medium","confidence_rationale":"Tier 2 — functional rescue in human iPSC-CMs with quantitative APD90 readout; proof-of-principle single study","pmids":["39069900"],"is_preprint":false},{"year":2024,"finding":"Cryo-EM structure of the UBR4–KCMF1–CALM1 complex (~1.3 MDa ring) revealed that CALM1 (calmodulin) is a structural cofactor of the UBR4 E4 ubiquitin ligase megacomplex, which extends K48-specific ubiquitin chains on substrate proteins. The architecture is conserved across eukaryotes with species-specific adaptations, and efficient substrate targeting requires both pre-ubiquitination and specific N-degrons with KCMF1 acting as substrate filter.","method":"Cryo-EM structural analysis; biochemical reconstitution; ubiquitination assays","journal":"bioRxiv (preprint)","confidence":"Medium","confidence_rationale":"Tier 1 — cryo-EM structure with biochemical validation; preprint, not yet peer-reviewed","pmids":["bio_10.1101_2024.12.18.629163"],"is_preprint":true},{"year":2025,"finding":"miR-202-3p directly targets Calm1 (validated by luciferase reporter assay) and suppresses Calm1 protein expression in murine lung tissue. In an LPS-induced ARDS mouse model, miR-202-3p overexpression reduced CALM1 protein levels, inactivated NF-κB/NLRP3 signaling, and attenuated pulmonary inflammation and edema, placing CALM1 upstream of the NF-κB/NLRP3 pathway in inflammatory lung injury.","method":"Luciferase reporter assay; Western blotting; immunohistochemistry; miR-202-3p agomir administration in C57BL/6 mice; LPS-induced ARDS model; measurement of NF-κB/NLRP3 signaling proteins","journal":"Cell Biochemistry and Biophysics","confidence":"Medium","confidence_rationale":"Tier 2–3 — validated miRNA-target interaction plus in vivo functional assay with signaling pathway readout; single lab","pmids":["38635101"],"is_preprint":false},{"year":2025,"finding":"Erianin (a natural compound) directly binds to CALM1 protein, enhancing its stability and subsequently increasing CAMKK2 phosphorylation. This CALM1/CAMKK2 axis activation promotes autophagy in 5-FU-resistant colorectal cancer cells, leading to tumor cell death and restored sensitivity to 5-FU.","method":"Drug-target binding assay; Western blotting for CALM1 stability and CAMKK2 phosphorylation; autophagy marker immunofluorescence; CCK8/EdU/Transwell proliferation and invasion assays; xenograft tumor model","journal":"Chemico-Biological Interactions","confidence":"Medium","confidence_rationale":"Tier 2–3 — direct binding assay plus downstream signaling and in vivo xenograft; single lab, limited mechanistic depth on binding site","pmids":["40976489"],"is_preprint":false},{"year":2025,"finding":"miR-205-5p promotes proliferation, migration, and invasion of nasopharyngeal carcinoma cells by directly targeting and suppressing CALM1 expression, validated by dual luciferase reporter assay. Inhibition of CALM1 by miR-205-5p mediates its oncogenic effects in NPC cells.","method":"Dual luciferase reporter assay; MTT, colony formation, Transwell assays; qRT-PCR and Western blot; overexpression in NPC cell lines","journal":"Critical Reviews in Immunology","confidence":"Low","confidence_rationale":"Tier 3 — luciferase validation of miRNA-target plus cell assays; no defined molecular mechanism downstream of CALM1 suppression; single lab","pmids":["39976516"],"is_preprint":false},{"year":2026,"finding":"CALM1/2 de novo variant c.419A>T (p.E140V) causes a neurological phenotype (hypotonia, motor delay, intellectual disability, abnormal EEG) without cardiac arrhythmia. RNA-seq showed the variant allele predominantly produces frameshifted C-terminal truncations via splice donor gain/intron retention (without NMD), with only a minority producing p.E140V missense protein. C. elegans cmd-1 modeling showed E140V has qualitatively and quantitatively different phenotypes from the arrhythmia variant E141G, indicating distinct molecular mechanisms for cardiac vs. neurological calmodulinopathy.","method":"Next-generation sequencing; RNA-seq of patient blood (splice analysis); C. elegans cmd-1 genetic modeling with phenotypic comparison of E140V vs. E141G","journal":"Human Molecular Genetics","confidence":"Medium","confidence_rationale":"Tier 2–3 — RNA-seq of patient tissue plus ortholog genetic modeling; mechanistic inference from combined data; two patients with same variant","pmids":["41467504"],"is_preprint":false},{"year":2026,"finding":"Ribosome profiling of human left ventricle tissue revealed that CALM1 and CALM2 each contribute ~44–45% of total cardiac calmodulin protein, while CALM3 contributes only ~11%, despite CALM3 being more actively transcribed than CALM2 relative to protein output in some tissues. This differential translation efficiency explains why CALM3 missense variants are clinically less severe and subject to weaker negative selection (observed/expected ratio 0.29 vs. 0.11 for CALM1) than CALM1 variants.","method":"Ribosome profiling of left ventricle tissue (GTEx); RNA-seq from 49 tissues; gnomAD variant analysis; International Calmodulinopathy Registry clinical data","journal":"Europace","confidence":"Medium","confidence_rationale":"Tier 2 — ribosome profiling provides direct translational efficiency measurement; supported by population-scale variant data and clinical registry","pmids":["41846582"],"is_preprint":false},{"year":2024,"finding":"Calmodulin missense variants in schizophrenia patients fall into two functional classes: (1) loss-of-function variants reducing Ca2+ affinity and impairing CaV1.2 gating (similar to but with smaller effect than LQTS variants), and (2) gain-of-function variants unexpectedly enhancing Ca2+ affinity with no impact on CaV1.2 gating. All schizophrenia-associated variants clustered in the C-terminal lobe of calmodulin.","method":"Large-scale sequencing (24,248 schizophrenia patients, 97,322 controls); Ca2+ affinity measurements; electrophysiological characterization of CaV1.2 gating","journal":"bioRxiv (preprint)","confidence":"Medium","confidence_rationale":"Tier 1–2 — biochemical Ca2+ affinity plus electrophysiology; preprint, statistical association modest (OR 5.62, P=0.043)","pmids":["bio_10.1101_2024.05.22.24307674"],"is_preprint":true}],"current_model":"CALM1 encodes calmodulin, a ubiquitous Ca2+ sensor that, upon Ca2+ binding, undergoes conformational change (unwinding of its central helix) to engulf target peptides in a hydrophobic tunnel, thereby activating targets including MLCK, SK channels (via N-lobe Ca2+ binding), eNOS (regulated by competitive phosphorylation of Thr495), and inhibiting NMDA receptors (via NR1 subunit binding reducing channel open probability ~4-fold); pathogenic CALM1 missense mutations (e.g. F142L, N98S, F90L) specifically impair Ca2+-dependent inactivation of cardiac CaV1.2 (L-type Ca2+ channel), leading to arrhythmias (long QT syndrome, ventricular fibrillation) through β-adrenergically exacerbated ICaL dysregulation, while CALM1 also functions as a structural subunit of the UBR4 E4 ubiquitin ligase complex, contributes ~45% of total cardiac calmodulin protein (the dominant source alongside CALM2), regulates axon elongation through local mRNA translation controlled by FMRP/miR-181d, drives precerebellar neuron migration in a gene-specific manner, and modulates NF-κB/NLRP3 inflammatory signaling."},"narrative":{"teleology":[{"year":1992,"claim":"The structural basis of calmodulin target recognition was established: Ca²⁺-bound CaM unwinds its central helix and wraps both lobes around a helical target peptide in a hydrophobic tunnel, explaining how a single sensor activates structurally diverse targets.","evidence":"2.4 Å X-ray crystal structure of Ca²⁺/CaM–MLCK peptide complex","pmids":["1519061"],"confidence":"High","gaps":["Structure captured a single target peptide; the mechanism of selectivity among hundreds of CaM targets was not resolved","Dynamics of the central helix unwinding in solution remained unknown"]},{"year":1993,"claim":"Genomic organization of the three human calmodulin genes was defined, mapping CALM1 to 14q24–q31 and showing that all three genes encode identical protein yet are dispersed across different chromosomes, raising the question of why three genes are maintained.","evidence":"PCR from somatic cell hybrids plus chromosomal in situ hybridization; Northern blot and promoter analysis of CALM1 gene structure","pmids":["8314583","7925473"],"confidence":"High","gaps":["Relative protein contributions of each CALM gene to total calmodulin were unknown","Functional redundancy versus gene-specific requirements not tested"]},{"year":1996,"claim":"CaM was identified as a direct Ca²⁺-dependent negative regulator of NMDA receptors, binding the NR1 subunit to reduce channel open probability ~4-fold and competing with the cytoskeletal anchor α-actinin-2 for the same NR1 binding site, establishing a feedback mechanism linking Ca²⁺ influx to receptor inactivation and cytoskeletal detachment.","evidence":"Patch-clamp electrophysiology of NR1/NR2 channels; co-immunoprecipitation from brain; in vitro competition binding with α-actinin-2","pmids":["8625412","9009191"],"confidence":"High","gaps":["In vivo significance of CaM–NR1 feedback for synaptic plasticity not demonstrated","Whether CALM1-specific mRNA regulation affects this process was unknown"]},{"year":1997,"claim":"CaM was shown to function as a constitutive, integral subunit of SK channels, with Ca²⁺ binding exclusively to the N-lobe EF hands triggering channel gating—the first demonstration that CaM acts as a permanent channel subunit rather than a transient activator.","evidence":"Biochemical binding assays; 1.60 Å crystal structure of CaMBD–Ca²⁺–CaM complex (2001)","pmids":["11323678"],"confidence":"High","gaps":["Whether CaM lobe-specificity generalizes to other channel targets was unclear","Isoform-specific contributions of CALM1/2/3 to SK channel CaM pools not addressed"]},{"year":2001,"claim":"The molecular switch controlling Ca²⁺/CaM-dependent eNOS activation was identified: constitutive PKC phosphorylation of Thr495 blocks CaM binding, while agonist-induced PP1 dephosphorylation permits CaM association and enzyme activation.","evidence":"Site-directed mutagenesis of Thr495, co-immunoprecipitation, pharmacological inhibition in porcine aortic endothelial cells","pmids":["11397791"],"confidence":"High","gaps":["Structural basis of how pThr495 sterically blocks CaM binding was not resolved","In vivo vascular consequences of Thr495 variants not tested"]},{"year":2013,"claim":"The first causative link between a CALM1 missense mutation (F90L) and a life-threatening cardiac arrhythmia (idiopathic ventricular fibrillation) was established, demonstrating that even heterozygous disruption of CaM–target interactions is pathogenic.","evidence":"Exome sequencing and pedigree analysis of affected family","pmids":["24076290"],"confidence":"Medium","gaps":["No functional reconstitution of F90L effect on specific ion channels in this study","Dominant-negative versus haploinsufficiency mechanism not distinguished"]},{"year":2015,"claim":"Axonal CALM1 mRNA translation was shown to be locally regulated by an FMRP/miR-181d repressive complex; NGF relieves this repression, promoting local calmodulin synthesis and axon elongation—establishing a gene-specific post-transcriptional mechanism for CALM1 in neural development.","evidence":"Co-IP of FMRP with miR-181d/Calm1 mRNA; Fmr1 KO and miR-181d overexpression; axonal fractionation in primary sensory neurons","pmids":["26711345"],"confidence":"Medium","gaps":["Whether CALM2/3 mRNAs are similarly regulated by FMRP/miRNAs was not tested","In vivo relevance for axon guidance phenotypes not demonstrated"]},{"year":2016,"claim":"The convergent arrhythmia mechanism of calmodulinopathy variants was defined: reduced Ca²⁺ affinity of mutant CaM causes dominant loss of Ca²⁺-dependent inactivation (CDI) of CaV1.2, with the E141G variant showing 11-fold reduced Ca²⁺ binding—while RyR2 function and NaV1.5 were only mildly affected, pinpointing CaV1.2 CDI as the primary arrhythmogenic target.","evidence":"Ca²⁺ binding affinity measurements; patch-clamp of CaV1.2, NaV1.5; RyR2 Ca²⁺ release assays in heterologous cells; patient iPSC-CM electrophysiology with verapamil rescue","pmids":["26969752","28158429"],"confidence":"High","gaps":["How a single mutant allele among six CALM alleles achieves dominant-negative effect on the CaV1.2 macromolecular complex was incompletely explained","Long-term remodeling effects in intact hearts not captured"]},{"year":2020,"claim":"A CRISPR knock-in mouse model (Calm1-N98S) demonstrated that β-adrenergic stimulation is the critical trigger for arrhythmogenesis: isoproterenol exacerbated ICaL density, slowed inactivation, and provoked both reentrant and focal arrhythmias (EADs, DADs), providing the first in vivo mechanistic model of calmodulinopathic LQTS.","evidence":"CRISPR/Cas9 heterozygous knock-in mice (two independent lines); ECG; optical voltage mapping; patch-clamp; Ca²⁺ imaging; His-Purkinje microelectrode recording","pmids":["32929985"],"confidence":"High","gaps":["Whether β-blocker therapy is sufficient to prevent sudden death long-term was not established","Tissue-specific contributions of CALM1 versus CALM2/3 in the mouse heart not quantified in this study"]},{"year":2024,"claim":"A SupRep gene therapy strategy—simultaneously knocking down all three CALM genes with shRNAs and replacing with shRNA-immune CALM1 cDNA—rescued prolonged APD in patient iPSC-CMs carrying mutations in any of the three CALM genes, establishing a unified therapeutic approach for calmodulinopathies.","evidence":"Lentiviral SupRep construct in iPSC-CMs from CALM1-F142L, CALM2-D130G, CALM3-D130G patients; voltage-sensing dye APD90 measurement","pmids":["39069900"],"confidence":"Medium","gaps":["In vivo delivery, long-term expression, and cardiac-specific targeting not demonstrated","Potential off-target effects of triple CALM knockdown on non-cardiac tissues not assessed"]},{"year":2025,"claim":"Ribosome profiling of human heart resolved the long-standing question of paralog contributions: CALM1 and CALM2 each supply ~45% of cardiac calmodulin protein while CALM3 contributes ~11%, explaining the greater clinical severity and stronger purifying selection on CALM1 variants.","evidence":"Ribosome profiling of left ventricle (GTEx); RNA-seq from 49 tissues; gnomAD constraint analysis; International Calmodulinopathy Registry","pmids":["41846582"],"confidence":"Medium","gaps":["Whether translational efficiency varies across cardiac cell types (atrial vs. ventricular vs. conduction system) is unknown","Developmental dynamics of CALM paralog translation not assessed"]},{"year":2026,"claim":"A neurological calmodulinopathy phenotype distinct from cardiac arrhythmia was attributed to a CALM1 variant (E140V) that predominantly generates aberrantly spliced, C-terminally truncated calmodulin rather than the missense protein—establishing that the molecular mechanism (splice disruption vs. Ca²⁺ affinity loss) determines tissue-specific disease outcome.","evidence":"RNA-seq of patient blood showing splice donor gain/intron retention; C. elegans cmd-1 modeling comparing E140V vs. E141G phenotypes","pmids":["41467504"],"confidence":"Medium","gaps":["Brain-specific expression of truncated calmodulin not directly confirmed (blood RNA-seq used)","How truncated CaM produces hypotonia and intellectual disability at the molecular level is unknown"]},{"year":null,"claim":"Key unresolved questions include: (1) how a single mutant CaM allele among six achieves dominant-negative effects on specific channel complexes in vivo, (2) the structural basis of CALM1 gene-specific functions in neuronal migration and axonal translation that are not compensated by CALM2/3, and (3) the physiological significance of CaM as a structural subunit of the UBR4 E4 ubiquitin ligase complex for substrate selection and protein homeostasis.","evidence":"","pmids":[],"confidence":"Medium","gaps":["Dominant-negative mechanism at the level of CaM–CaV1.2 stoichiometry not quantitatively modeled in vivo","CALM1-specific neuronal functions may reflect 3'UTR/5'UTR-mediated mRNA regulation rather than protein-level differences, but this has not been directly tested","UBR4–KCMF1–CaM complex function awaits peer-reviewed validation and identification of endogenous substrates"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,1,2,5,13,14,15]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[3]},{"term_id":"GO:0140299","term_label":"molecular sensor activity","supporting_discovery_ids":[0,2,13]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[4,12]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[4]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1,2,14]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,2,5,13,15,18]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[1,3,11,12]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[11,12]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[18]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[17]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[10,13,14,15,21]}],"complexes":["SK channel complex","UBR4–KCMF1–CaM E4 ligase complex"],"partners":["GRIN1","KCNN2","NOS3","CACNA1C","ACTN2","FMRP","UBR4","KCMF1"],"other_free_text":[]},"mechanistic_narrative":"CALM1 encodes calmodulin-1, one of three genes producing the identical 149-residue Ca²⁺-sensing protein calmodulin, which transduces intracellular calcium signals by undergoing a conformational change—unwinding its central helix to form a hydrophobic tunnel that engulfs target peptides—thereby activating or inhibiting diverse effectors including smooth muscle MLCK, SK potassium channels (gated by N-lobe Ca²⁺ binding), eNOS (regulated by PKC-mediated Thr495 phosphorylation), and NMDA receptors (where Ca²⁺/CaM binding to NR1 reduces channel open probability ~4-fold) [PMID:1519061, PMID:8625412, PMID:11323678, PMID:11397791]. CALM1 contributes approximately 45% of total cardiac calmodulin protein and is the dominant translational source alongside CALM2; missense mutations (e.g., F142L, N98S, F90L) that reduce Ca²⁺ affinity cause dominant impairment of Ca²⁺-dependent inactivation of the cardiac L-type calcium channel CaV1.2, producing long QT syndrome and catecholaminergic ventricular arrhythmias exacerbated by β-adrenergic stimulation [PMID:41846582, PMID:32929985, PMID:28158429, PMID:26969752]. Beyond the heart, CALM1 has gene-specific roles in precerebellar neuron migration not compensated by CALM2/3, and its axonal translation is locally controlled by an FMRP/miR-181d repression complex that is relieved by NGF to promote axon elongation [PMID:25519244, PMID:26711345]. A de novo CALM1 variant (p.E140V) causes a neurological phenotype (hypotonia, intellectual disability) without cardiac arrhythmia, through aberrant splicing producing C-terminally truncated calmodulin, establishing genotype-specific mechanisms for cardiac versus neurological calmodulinopathy [PMID:41467504]."},"prefetch_data":{"uniprot":{"accession":"P0DP23","full_name":"Calmodulin-1","aliases":[],"length_aa":149,"mass_kda":16.8,"function":"Calmodulin acts as part of a calcium signal transduction pathway by mediating the control of a large number of enzymes, ion channels, aquaporins and other proteins through calcium-binding (PubMed:16760425, PubMed:23893133, PubMed:26969752, PubMed:27165696, PubMed:28890335, PubMed:31454269, PubMed:35568036). Calcium-binding is required for the activation of calmodulin (PubMed:16760425, PubMed:23893133, PubMed:26969752, PubMed:27165696, PubMed:28890335, PubMed:31454269, PubMed:35568036). Among the enzymes to be stimulated by the calmodulin-calcium complex are a number of protein kinases, such as myosin light-chain kinases and calmodulin-dependent protein kinase type II (CaMK2), and phosphatases (PubMed:16760425, PubMed:23893133, PubMed:26969752, PubMed:27165696, PubMed:28890335, PubMed:31454269, PubMed:35568036). Together with CCP110 and centrin, is involved in a genetic pathway that regulates the centrosome cycle and progression through cytokinesis (PubMed:16760425). Is a regulator of voltage-dependent L-type calcium channels (PubMed:31454269). Mediates calcium-dependent inactivation of CACNA1C (PubMed:26969752). Positively regulates calcium-activated potassium channel activity of KCNN2 (PubMed:27165696). Forms a potassium channel complex with KCNQ1 and regulates electrophysiological activity of the channel via calcium-binding (PubMed:25441029). Acts as a sensor to modulate the endoplasmic reticulum contacts with other organelles mediated by VMP1:ATP2A2 (PubMed:28890335) (Microbial infection) Required for Legionella pneumophila SidJ glutamylase activity (Microbial infection) Required for C.violaceum CopC and S.flexneri OspC3 arginine ADP-riboxanase activity","subcellular_location":"Cytoplasm, cytoskeleton, spindle; Cytoplasm, cytoskeleton, spindle pole; Cytoplasm, cytoskeleton, microtubule organizing center, centrosome; Cell projection, cilium, flagellum","url":"https://www.uniprot.org/uniprotkb/P0DP23/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CALM1","classification":"Not Classified","n_dependent_lines":6,"n_total_lines":1208,"dependency_fraction":0.004966887417218543},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000198668","cell_line_id":"CID000357","localizations":[{"compartment":"cell_contact","grade":3},{"compartment":"centrosome","grade":3},{"compartment":"cytoplasmic","grade":3},{"compartment":"nucleoplasm","grade":3},{"compartment":"membrane","grade":1}],"interactors":[{"gene":"MYL6","stoichiometry":10.0},{"gene":"CALM2;CALM3;CALM1","stoichiometry":10.0},{"gene":"DENND4C","stoichiometry":0.2},{"gene":"UBR4","stoichiometry":0.2},{"gene":"ANKS6","stoichiometry":0.2},{"gene":"KIF1BBETA;KIF1B","stoichiometry":0.2},{"gene":"ESCO1","stoichiometry":0.2},{"gene":"ASPM","stoichiometry":0.2},{"gene":"PLEKHH2","stoichiometry":0.2},{"gene":"CEP97","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID000357","total_profiled":1310},"omim":[{"mim_id":"618807","title":"LIPOPROTEIN(a) QUANTITATIVE TRAIT LOCUS; LPAQTL","url":"https://www.omim.org/entry/618807"},{"mim_id":"618782","title":"LONG QT SYNDROME 16; LQT16","url":"https://www.omim.org/entry/618782"},{"mim_id":"618759","title":"CALCIUM-BINDING PROTEIN 7; CABP7","url":"https://www.omim.org/entry/618759"},{"mim_id":"617631","title":"IQ DOMAIN-CONTAINING PROTEIN E; IQCE","url":"https://www.omim.org/entry/617631"},{"mim_id":"617379","title":"MYOSIN XIX; MYO19","url":"https://www.omim.org/entry/617379"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/CALM1"},"hgnc":{"alias_symbol":["CAMI","PHKD","DD132","PHKD1"],"prev_symbol":["CALML2"]},"alphafold":{"accession":"P0DP23","domains":[{"cath_id":"1.10.238.10","chopping":"1-78","consensus_level":"high","plddt":83.4442,"start":1,"end":78},{"cath_id":"1.10.238.10","chopping":"94-146","consensus_level":"high","plddt":91.1268,"start":94,"end":146}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P0DP23","model_url":"https://alphafold.ebi.ac.uk/files/AF-P0DP23-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P0DP23-F1-predicted_aligned_error_v6.png","plddt_mean":85.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CALM1","jax_strain_url":"https://www.jax.org/strain/search?query=CALM1"},"sequence":{"accession":"P0DP23","fasta_url":"https://rest.uniprot.org/uniprotkb/P0DP23.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P0DP23/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P0DP23"}},"corpus_meta":[{"pmid":"24076290","id":"PMC_24076290","title":"A mutation in CALM1 encoding calmodulin in familial idiopathic ventricular fibrillation in childhood and adolescence.","date":"2013","source":"Journal of the American College of Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/24076290","citation_count":136,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26969752","id":"PMC_26969752","title":"Spectrum and Prevalence of CALM1-, CALM2-, and CALM3-Encoded Calmodulin Variants in Long QT Syndrome and Functional Characterization of a Novel Long QT Syndrome-Associated Calmodulin Missense Variant, E141G.","date":"2016","source":"Circulation. Cardiovascular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26969752","citation_count":109,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28158429","id":"PMC_28158429","title":"Elucidating arrhythmogenic mechanisms of long-QT syndrome CALM1-F142L mutation in patient-specific induced pluripotent stem cell-derived cardiomyocytes.","date":"2017","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/28158429","citation_count":104,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15746150","id":"PMC_15746150","title":"A functional single nucleotide polymorphism in the core promoter region of CALM1 is associated with hip osteoarthritis in Japanese.","date":"2005","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15746150","citation_count":92,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8314583","id":"PMC_8314583","title":"Localization of the human bona fide calmodulin genes CALM1, CALM2, and CALM3 to chromosomes 14q24-q31, 2p21.1-p21.3, and 19q13.2-q13.3.","date":"1993","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8314583","citation_count":80,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26711345","id":"PMC_26711345","title":"FMRP-Mediated Axonal Delivery of miR-181d Regulates Axon Elongation by Locally Targeting Map1b and Calm1.","date":"2015","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/26711345","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9681195","id":"PMC_9681195","title":"Characterization of the human CALM2 calmodulin gene and comparison of the transcriptional activity of CALM1, CALM2 and CALM3.","date":"1998","source":"Cell calcium","url":"https://pubmed.ncbi.nlm.nih.gov/9681195","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33778017","id":"PMC_33778017","title":"C-Reactive Protein Apheresis as Anti-inflammatory Therapy in Acute Myocardial Infarction: Results of the CAMI-1 Study.","date":"2021","source":"Frontiers in cardiovascular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33778017","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7750312","id":"PMC_7750312","title":"Cocaine-associated myocardial infarction. Clinical safety of thrombolytic therapy. Cocaine Associated Myocardial Infarction (CAMI) Study Group.","date":"1995","source":"Chest","url":"https://pubmed.ncbi.nlm.nih.gov/7750312","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25519244","id":"PMC_25519244","title":"Calm1 signaling pathway is essential for the migration of mouse precerebellar neurons.","date":"2014","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/25519244","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16359877","id":"PMC_16359877","title":"The CALM1 core promoter polymorphism is not associated with hip osteoarthritis in a United Kingdom Caucasian population.","date":"2005","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/16359877","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32522888","id":"PMC_32522888","title":"Elimination of Calm1 long 3'-UTR mRNA isoform by CRISPR-Cas9 gene editing impairs dorsal root ganglion development and hippocampal neuron activation in mice.","date":"2020","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/32522888","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17310335","id":"PMC_17310335","title":"CaMi, a root-knot nematode resistance gene from hot pepper (Capsium annuum L.) confers nematode resistance in tomato.","date":"2007","source":"Plant cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/17310335","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7925473","id":"PMC_7925473","title":"Structure of the human CALM1 calmodulin gene and identification of two CALM1-related pseudogenes CALM1P1 and CALM1P2.","date":"1994","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7925473","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33602237","id":"PMC_33602237","title":"CALM1 promotes progression and dampens chemosensitivity to EGFR inhibitor in esophageal squamous cell carcinoma.","date":"2021","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/33602237","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26196381","id":"PMC_26196381","title":"Common Variants in TRDN and CALM1 Are Associated with Risk of Sudden Cardiac Death in Chronic Heart Failure Patients in Chinese Han Population.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26196381","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32929985","id":"PMC_32929985","title":"Complex Arrhythmia Syndrome in a Knock-In Mouse Model Carrier of the N98S Calm1 Mutation.","date":"2020","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/32929985","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36530083","id":"PMC_36530083","title":"Novel Genetic Variants in TP37, PIK3R1, CALM1, and PLCG2 of the Neurotrophin Signaling Pathway Are Associated with the Progression from Mild Cognitive Impairment to Alzheimer's Disease.","date":"2023","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/36530083","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22285581","id":"PMC_22285581","title":"Risk stratification of ischaemic patients with implantable cardioverter defibrillators by C-reactive protein and a multi-markers strategy: results of the CAMI-GUIDE study.","date":"2012","source":"European heart journal","url":"https://pubmed.ncbi.nlm.nih.gov/22285581","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18452398","id":"PMC_18452398","title":"Association of the CALM1 core promoter polymorphism with knee osteoarthritis in patients of Greek origin.","date":"2008","source":"Genetic testing","url":"https://pubmed.ncbi.nlm.nih.gov/18452398","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29899463","id":"PMC_29899463","title":"The CAMI-score: A Novel Tool derived From CAMI Registry to Predict In-hospital Death among Acute Myocardial Infarction Patients.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29899463","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37406751","id":"PMC_37406751","title":"Changes in urinary exosomal protein CALM1 may serve as an early noninvasive biomarker for diagnosing diabetic kidney disease.","date":"2023","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37406751","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29713907","id":"PMC_29713907","title":"Association of CALM1 rs3179089 Polymorphism with Ischemic Stroke in Chinese Han Population.","date":"2018","source":"Neuromolecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29713907","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39069900","id":"PMC_39069900","title":"Single Construct Suppression and Replacement Gene Therapy for the Treatment of All CALM1-, CALM2-, and CALM3-Mediated Arrhythmia Disorders.","date":"2024","source":"Circulation. Arrhythmia and electrophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/39069900","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18940010","id":"PMC_18940010","title":"Lack of association between the CALM1 core promoter polymorphism (-16C/T) and susceptibility to knee osteoarthritis in a Chinese Han population.","date":"2008","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18940010","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30200150","id":"PMC_30200150","title":"The association between rs12885713 polymorphism in CALM1 and risk of osteoarthritis: A meta-analysis of case-control studies.","date":"2018","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30200150","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33634591","id":"PMC_33634591","title":"14q32.11 microdeletion including CALM1, TTC7B, PSMC1, and RPS6KA5: A new potential cause of developmental and language delay in three unrelated patients.","date":"2021","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/33634591","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9533020","id":"PMC_9533020","title":"Assignment of TCF1, TGM1, CALM1, CKB, THBS1, B2M, and FES in Ateles paniscus chamek (Platyrrhini, Primates).","date":"1997","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9533020","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30279205","id":"PMC_30279205","title":"Association between the polymorphisms of CALM1 gene and osteoarthritis risk: a meta-analysis based on observational studies.","date":"2018","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/30279205","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18001530","id":"PMC_18001530","title":"[Is polymorphism of CALM1 gene or growth hormone receptor gene associated with susceptibility to adolescent idiopathic scoliosis?].","date":"2007","source":"Zhonghua yi xue za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/18001530","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34338988","id":"PMC_34338988","title":"CALM1 rs3179089 polymorphism might contribute to coronary artery disease susceptibility in Chinese male: a case-control study.","date":"2021","source":"Genes & genomics","url":"https://pubmed.ncbi.nlm.nih.gov/34338988","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39976516","id":"PMC_39976516","title":"miR-205-5p Promotes the Proliferation, Migration, and Invasion of Nasopharyngeal Carcinoma Cells by Regulating CALM1.","date":"2025","source":"Critical reviews in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39976516","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34860437","id":"PMC_34860437","title":"Mutational spectrum of congenital long QT syndrome in Turkey; identification of 12 novel mutations across KCNQ1, KCNH2, SCN5A, KCNJ2, CACNA1C, and CALM1.","date":"2021","source":"Journal of cardiovascular electrophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/34860437","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38635101","id":"PMC_38635101","title":"MiR-202-3p Targets Calm1 and Suppresses Inflammation in a Mouse Model of Acute Respiratory Distress Syndrome.","date":"2024","source":"Cell biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/38635101","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37905352","id":"PMC_37905352","title":"Case report of a child with long QT syndrome type 14 caused by CALM1 gene mutation and literature review.","date":"2023","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37905352","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41181366","id":"PMC_41181366","title":"Lactylation-Related Gene CALM1 Promotes Aortic Dissection via Immune Microenvironment Remodeling: Insights from Bioinformatics and Clinical Evidence.","date":"2025","source":"Journal of inflammation research","url":"https://pubmed.ncbi.nlm.nih.gov/41181366","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40976489","id":"PMC_40976489","title":"Erianin reverses 5-FU resistance by targeting CALM1/CAMKK2 and activating autophagy in colorectal cancer.","date":"2025","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/40976489","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41444788","id":"PMC_41444788","title":"Compact Calm1 promoter enables AAV mediated neuron-targeted expression in human iPSC-derived brain organoids.","date":"2025","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/41444788","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11808628","id":"PMC_11808628","title":"Chromosomal mapping of calmodulin 1 (CALM1) and alpha-globin 1 genes (HBA1) in the bovine.","date":"2001","source":"Animal biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/11808628","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26424005","id":"PMC_26424005","title":"High genetic abundance of Rpi-blb2/Mi-1.2/Cami gene family in Solanaceae.","date":"2015","source":"BMC evolutionary biology","url":"https://pubmed.ncbi.nlm.nih.gov/26424005","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40070855","id":"PMC_40070855","title":"A Pilot Study of ANXA2, MED12, CALM1 and MAPK1 Gene Variants in Primary Hyperparathyroidism.","date":"2025","source":"Balkan journal of medical genetics : BJMG","url":"https://pubmed.ncbi.nlm.nih.gov/40070855","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41525860","id":"PMC_41525860","title":"Genetic and metabolic regulation of eggshell quality in aging hens: Integrated multi-omics insights into CYP7A1, CALM1, and cholic/stearic acid metabolism.","date":"2026","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/41525860","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41467504","id":"PMC_41467504","title":"Phenotypic expansion of CALM1/2-associated disorders to include neurologic phenotypes without arrhythmia.","date":"2026","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/41467504","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41846582","id":"PMC_41846582","title":"CALM1, CALM2, and CALM3 expression and translation efficiency provide insight into the severity of calmodulinopathy.","date":"2026","source":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/41846582","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.10.10.25337746","title":"One year later: Tracking the continued growth of mental illness stigma in England","date":"2025-10-13","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.10.25337746","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.05.15.25327594","title":"<i>CALM1, CALM2,</i>and<i>CALM3</i>expression and translation efficiency provide insight into the severity of calmodulinopathy","date":"2025-05-15","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.15.25327594","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.07.14.664802","title":"<i>Leviathan</i>: A fast, memory-efficient, and scalable taxonomic and pathway profiler for (pan)genome-resolved metagenomics and metatranscriptomics","date":"2025-07-18","source":"bioRxiv","url":"https://doi.org/10.1101/2025.07.14.664802","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2024.12.18.629163","title":"Architecture of the UBR4 complex, a giant E4 ligase central to eukaryotic protein quality control","date":"2024-12-20","source":"bioRxiv","url":"https://doi.org/10.1101/2024.12.18.629163","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.04.13.648563","title":"Sustained Antigen Stimulation to Evoke and Study Negative feedback Systems responsible for Self-Tolerance/Tumor Immune Escape and transition to the M2 macrophage","date":"2025-04-18","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.13.648563","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.01.21.634109","title":"Mapping brain function underlying naturalistic motor observation and imitation using high-density diffuse optical tomography","date":"2025-01-22","source":"bioRxiv","url":"https://doi.org/10.1101/2025.01.21.634109","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.04.20.649691","title":"CompleteBin: A transformer-based framework unlocks microbial dark matter through improved short contig binning","date":"2025-04-24","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.20.649691","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.02.07.637187","title":"DeepMM: Identify and correct Metagenome Misassemblies with deep learning","date":"2025-02-08","source":"bioRxiv","url":"https://doi.org/10.1101/2025.02.07.637187","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2024.05.22.24307674","title":"Calmodulin variants in schizophrenia patients display gain-of-function or loss-of-function effects","date":"2024-05-22","source":"bioRxiv","url":"https://doi.org/10.1101/2024.05.22.24307674","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":"27535533","id":"PMC_27535533","title":"Analysis of protein-coding genetic variation in 60,706 humans.","date":"2016","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/27535533","citation_count":7914,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9278050","id":"PMC_9278050","title":"Fluorescent indicators for Ca2+ based on green fluorescent proteins and calmodulin.","date":"1997","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/9278050","citation_count":2324,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16189514","id":"PMC_16189514","title":"Towards a proteome-scale map of the human protein-protein interaction network.","date":"2005","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/16189514","citation_count":2090,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22658674","id":"PMC_22658674","title":"Insights into RNA biology from an atlas of mammalian mRNA-binding proteins.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22658674","citation_count":1718,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20562859","id":"PMC_20562859","title":"Network organization of the human autophagy system.","date":"2010","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/20562859","citation_count":1286,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19615732","id":"PMC_19615732","title":"Defining the human deubiquitinating enzyme interaction landscape.","date":"2009","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/19615732","citation_count":1282,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26496610","id":"PMC_26496610","title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26496610","citation_count":1015,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25416956","id":"PMC_25416956","title":"A proteome-scale map of the human interactome network.","date":"2014","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/25416956","citation_count":977,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1519061","id":"PMC_1519061","title":"Target enzyme recognition by calmodulin: 2.4 A structure of a calmodulin-peptide complex.","date":"1992","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/1519061","citation_count":950,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14743216","id":"PMC_14743216","title":"A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway.","date":"2004","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/14743216","citation_count":841,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17353931","id":"PMC_17353931","title":"Large-scale mapping of human protein-protein interactions by mass spectrometry.","date":"2007","source":"Molecular systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/17353931","citation_count":733,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22939629","id":"PMC_22939629","title":"A census of human soluble protein complexes.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22939629","citation_count":689,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11397791","id":"PMC_11397791","title":"Phosphorylation of Thr(495) regulates Ca(2+)/calmodulin-dependent endothelial nitric oxide synthase activity.","date":"2001","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/11397791","citation_count":618,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21565611","id":"PMC_21565611","title":"Mapping the NPHP-JBTS-MKS protein network reveals ciliopathy disease genes and pathways.","date":"2011","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/21565611","citation_count":507,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9009191","id":"PMC_9009191","title":"Competitive binding of alpha-actinin and calmodulin to the NMDA receptor.","date":"1997","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/9009191","citation_count":505,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11323678","id":"PMC_11323678","title":"Structure of the gating domain of a Ca2+-activated K+ channel complexed with Ca2+/calmodulin.","date":"2001","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/11323678","citation_count":500,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8625412","id":"PMC_8625412","title":"Inactivation of NMDA receptors by direct interaction of calmodulin with the NR1 subunit.","date":"1996","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/8625412","citation_count":465,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26638075","id":"PMC_26638075","title":"A Dynamic Protein Interaction Landscape of the Human Centrosome-Cilium Interface.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26638075","citation_count":433,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"35271311","id":"PMC_35271311","title":"OpenCell: Endogenous tagging for the cartography of human cellular organization.","date":"2022","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/35271311","citation_count":432,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12408866","id":"PMC_12408866","title":"Dual regulation of NMDA receptor functions by direct protein-protein interactions with the dopamine D1 receptor.","date":"2002","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/12408866","citation_count":427,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16344560","id":"PMC_16344560","title":"Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.","date":"2005","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16344560","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17719545","id":"PMC_17719545","title":"Cep97 and CP110 suppress a cilia assembly program.","date":"2007","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/17719545","citation_count":386,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19596235","id":"PMC_19596235","title":"Mammalian BTBD12/SLX4 assembles a Holliday junction resolvase and is required for DNA repair.","date":"2009","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/19596235","citation_count":375,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2161834","id":"PMC_2161834","title":"Smooth muscle calponin. Inhibition of actomyosin MgATPase and regulation by phosphorylation.","date":"1990","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2161834","citation_count":374,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14744259","id":"PMC_14744259","title":"14-3-3-affinity purification of over 200 human phosphoproteins reveals new links to regulation of cellular metabolism, proliferation and trafficking.","date":"2004","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/14744259","citation_count":372,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17620599","id":"PMC_17620599","title":"Functional specialization of beta-arrestin interactions revealed by proteomic analysis.","date":"2007","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/17620599","citation_count":360,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":29646,"output_tokens":4545,"usd":0.078557},"stage2":{"model":"claude-opus-4-6","input_tokens":7982,"output_tokens":3524,"usd":0.192015},"total_usd":0.627751,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":41524,"output_tokens":8797,"usd":0.128264},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":10752,"output_tokens":3954,"usd":0.228915}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2013,\n      \"finding\": \"The CALM1 F90L missense mutation causes familial idiopathic ventricular fibrillation; F90 mediates the direct interaction of calmodulin with target peptides, and its mutation disrupts this interaction.\",\n      \"method\": \"Exome sequencing, functional inference from known structural data on CaM-target interactions\",\n      \"journal\": \"Journal of the American College of Cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic identification with mechanistic support from prior structural literature; single family study\",\n      \"pmids\": [\"24076290\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CALM1/2/3 pathogenic variants (e.g., E141G) reduce calmodulin Ca2+-binding affinity and cause loss of Ca2+-dependent inactivation (CDI) of the cardiac L-type calcium channel CaV1.2, with mild accentuation of NaV1.5 late current, but no effect on RyR2-mediated calcium release.\",\n      \"method\": \"Whole-exome sequencing, fluorescence-based Ca2+-binding assay, patch-clamp electrophysiology in heterologous cells\",\n      \"journal\": \"Circulation. Cardiovascular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (Ca2+ affinity assay, CaV1.2 patch clamp, NaV1.5 current, RyR2 calcium release) in a single study\",\n      \"pmids\": [\"26969752\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"The CALM1-F142L mutation impairs Ca2+-dependent inactivation (CDI) of ICaL in human iPSC-derived cardiomyocytes, prolonging action potential repolarization with altered rate-dependency; IKs, INaL, and intracellular Ca2+ dynamics were not significantly affected; repolarization abnormalities were reversed by verapamil (ICaL blockade).\",\n      \"method\": \"hiPSC-CM differentiation, patch-clamp electrophysiology (ICaL CDI, IKs, INaL, If), dynamic clamp, intracellular Ca2+ fluorescence imaging, pharmacological rescue\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — patient-derived iPSC-CMs with multiple orthogonal electrophysiological and pharmacological validations\",\n      \"pmids\": [\"28158429\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"A functional SNP (-16C>T) in the CALM1 core promoter reduces CALM1 transcription in vitro and in vivo; inhibition of calmodulin in chondrogenic cells reduced expression of cartilage matrix genes Col2a1 and Agc1, placing CALM1-mediated signaling upstream of chondrogenic gene expression.\",\n      \"method\": \"Reporter gene (luciferase) transfection, allele-specific transcription assay, siRNA/pharmacological CaM inhibition in chondrogenic cells, RT-PCR for Col2a1/Agc1\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal functional assays (promoter reporter, in vivo expression, CaM inhibition with downstream gene readout)\",\n      \"pmids\": [\"15746150\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"FMRP associates with miR-181d, Map1b mRNA, and Calm1 mRNA, mediating axonal delivery of miR-181d which locally suppresses translation of Calm1 and Map1b in axons to negatively regulate axon elongation; NGF releases Calm1 mRNA from FMRP/miR-181d repressing granules to promote elongation.\",\n      \"method\": \"Co-IP (FMRP with miR-181d, Map1b, Calm1), axonal localization by subcellular fractionation, Fmr1 KO/knockdown with protein level measurement, NGF stimulation assay in primary sensory neurons\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP, KO/KD models, NGF stimulation, multiple orthogonal methods across genetic and pharmacological perturbations\",\n      \"pmids\": [\"26711345\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Calm1-specific RNAi knockdown (but not Calm2 or Calm3 knockdown) causes defective circumferential tangential migration and failure of radial migration in mouse precerebellar neurons, demonstrating a non-redundant, gene-specific role of Calm1 in neuronal migration.\",\n      \"method\": \"In vivo RNAi-mediated knockdown of individual Calm genes in mouse embryos, histological analysis of precerebellar neuron positioning\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean gene-specific KD in vivo with defined cellular migration phenotype and specificity controls (Calm2, Calm3 knockdown as comparators)\",\n      \"pmids\": [\"25519244\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CRISPR-Cas9 deletion of the Calm1 distal poly(A) site eliminates the long 3'-UTR isoform (Calm1-L) while maintaining the short isoform (Calm1-S); loss of Calm1-L causes disorganized DRG migration in embryos and reduced experience-induced neuronal activation in adult hippocampus, demonstrating isoform-specific neural functions.\",\n      \"method\": \"CRISPR-Cas9 gene editing, smFISH for subcellular isoform localization, histological analysis of DRG migration, immediate early gene activation assay in hippocampus\",\n      \"journal\": \"RNA (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — CRISPR knock-in mouse model with multiple orthogonal readouts (localization, migration, neuronal activation)\",\n      \"pmids\": [\"32522888\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Heterozygous Calm1-N98S knock-in mice exhibit sinus bradycardia, QTc prolongation, and catecholaminergic bidirectional ventricular tachycardia; β-adrenergic stimulation increases peak ICa.L density, slows inactivation, and left-shifts activation, increasing late ICa.L; His-Purkinje fibers show pause-dependent early afterdepolarizations and ventricular myocytes show tachycardia-induced delayed afterdepolarizations, contributing to arrhythmogenesis via both reentry and focal mechanisms.\",\n      \"method\": \"CRISPR/Cas9 knock-in mouse model, ECG monitoring, optical voltage mapping, patch-clamp (ICa.L, whole-cell currents), fluorescence Ca2+ imaging, microelectrode recording of His-Purkinje fibers, β-adrenergic pharmacology\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — two independent knock-in mouse lines, multiple orthogonal electrophysiological and pharmacological methods\",\n      \"pmids\": [\"32929985\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CALM1 is a component of the UBR4-KCMF1-CALM1 E4 ubiquitin ligase megacomplex (~1.3 MDa ring structure); cryo-EM reveals CALM1 as a structural cofactor within this complex that mediates substrate targeting and K48-specific ubiquitin chain extension for protein quality control.\",\n      \"method\": \"Cryo-EM structural determination of the UBR4-KCMF1-CALM1 complex, in vitro ubiquitination assay, mutagenesis\",\n      \"journal\": \"bioRxiv (preprint)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cryo-EM structure plus in vitro reconstitution and functional assays in a single study\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"A suppression-replacement (SupRep) gene therapy using shRNAs targeting CALM1 (86% KD), CALM2 (71% KD), and CALM3 (94% KD) together with a shRNA-immune CALM1 cDNA replacement shortens pathologically prolonged APD90 in CALM1-F142L, CALM2-D130G, and CALM3-D130G iPSC-derived cardiomyocytes, demonstrating that a single CALM1-based replacement can rescue all three calmodulinopathy variants.\",\n      \"method\": \"shRNA knockdown efficiency assay (RT-qPCR), patient iPSC-derived cardiomyocyte differentiation, voltage-sensing dye APD90 measurement, AAV-delivered SupRep construct\",\n      \"journal\": \"Circulation. Arrhythmia and electrophysiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple patient iPSC-CM lines, quantitative APD readout, shRNA specificity controls across three genes\",\n      \"pmids\": [\"39069900\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Erianin binds directly to CALM1 protein, enhances its stability, and increases CAMKK2 phosphorylation, thereby activating autophagy in 5-FU-resistant colorectal cancer cells and restoring chemosensitivity; this places CALM1 upstream of CAMKK2-mediated autophagy induction.\",\n      \"method\": \"CCK8 assay, Western blotting (CALM1 protein, phospho-CAMKK2, autophagy markers), immunofluorescence, qRT-PCR, xenograft tumor model, direct binding assay (Erianin-CALM1 interaction)\",\n      \"journal\": \"Chemico-biological interactions\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — in vitro and in vivo functional assays with mechanistic pathway placement, but direct binding characterization details limited\",\n      \"pmids\": [\"40976489\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Calmodulin missense variants identified in schizophrenia patients fall into two functional classes: loss-of-function variants that reduce Ca2+ affinity and impair CaV1.2 gating (similar to LQTS variants but smaller effect), and gain-of-function variants that enhance Ca2+ affinity without impacting CaV1.2 gating; all schizophrenia variants affect the C-terminal lobe of calmodulin.\",\n      \"method\": \"Large-scale sequencing (24,248 cases, 97,322 controls), fluorescence-based Ca2+-binding assay, patch-clamp electrophysiology (CaV1.2 gating), statistical enrichment analysis\",\n      \"journal\": \"bioRxiv (preprint)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — functional Ca2+ affinity and CaV1.2 patch-clamp assays on multiple variants; single study, preprint\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"miR-202-3p directly targets Calm1 (validated by luciferase reporter assay); overexpression of miR-202-3p suppresses Calm1 protein, inactivates NF-κB/NLRP3 signaling, and reduces lung inflammation in LPS-induced ARDS mouse model.\",\n      \"method\": \"Luciferase reporter assay (miR-202-3p binding to Calm1 3'-UTR), Western blotting, immunohistochemistry, mouse LPS-ARDS model, miR-202-3p agomir delivery\",\n      \"journal\": \"Cell biochemistry and biophysics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — direct binding validated by luciferase assay plus in vivo rescue, but mechanistic pathway (Calm1→NF-κB/NLRP3) established primarily by expression changes\",\n      \"pmids\": [\"38635101\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"The three human calmodulin genes CALM1, CALM2, and CALM3 are located on distinct chromosomes (14q24-q31, 2p21.1-p21.3, and 19q13.2-q13.3, respectively), establishing that they are non-allelic and were dispersed from an ancestral precursor gene.\",\n      \"method\": \"PCR amplification from human-hamster somatic cell hybrids, fluorescence in situ hybridization (FISH) on human metaphase spreads\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct chromosomal mapping with two orthogonal methods (somatic cell hybrids + FISH), foundational study\",\n      \"pmids\": [\"8314583\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"The human CALM1 gene contains six exons spread over ~10 kb, with a cluster of transcription start sites 200 bp upstream of the ATG, and is expressed in all human tissues tested; a 1.7-kb mRNA is uniformly expressed while a 4.2-kb mRNA is particularly abundant in brain and skeletal muscle; two intronless pseudogenes (CALM1P1 and CALM1P2) were also identified.\",\n      \"method\": \"Genomic library screening, exon-intron boundary sequencing, Northern blotting of multiple tissues, 5' mapping of transcription start sites\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct gene structure determination with tissue expression profiling; foundational genomic characterization\",\n      \"pmids\": [\"7925473\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"CALM3 is at least 5-fold more actively transcribed than CALM1 or CALM2 in proliferating human teratoma cells; the 5' untranslated regions are necessary for full promoter activation in transient transfection assays, demonstrating differential transcriptional regulation of the three CALM genes.\",\n      \"method\": \"Run-on transcription assay, mRNA abundance measurement, luciferase reporter transfection with and without 5' UTR\",\n      \"journal\": \"Cell calcium\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (run-on transcription, mRNA quantification, promoter reporter) in same study\",\n      \"pmids\": [\"9681195\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"CALM1 contributes ~44-45% and CALM2 ~44% of total calmodulin protein in the human left ventricle, while CALM3 contributes only ~11%, based on ribosome profiling; CALM3 is under less negative selection (observed-to-expected missense ratio 0.29 vs. 0.11 for CALM1), consistent with CALM1 missense variant carriers having the highest rate of cardiac events (89%) compared to CALM2 (70%) and CALM3 (57%).\",\n      \"method\": \"GTEx RNA-seq (mRNA abundance), ribosome profiling of left ventricle tissue, gnomAD population constraint analysis, International Calmodulinopathy Registry clinical data\",\n      \"journal\": \"Europace\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ribosome profiling combined with population genetics and clinical registry data; peer-reviewed with large datasets\",\n      \"pmids\": [\"41846582\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CALM1 encodes one of three genes producing identical calmodulin protein; it is the dominant contributor (~45%) to total calmodulin in the human heart and acts as a multifunctional Ca2+ sensor that directly regulates CaV1.2 L-type calcium channel Ca2+-dependent inactivation (CDI), NaV1.5 late current, and CAMKK2 phosphorylation; pathogenic missense mutations reduce Ca2+-binding affinity and impair CaV1.2 CDI, causing prolonged cardiac repolarization and arrhythmia (long QT syndrome, ventricular fibrillation, CPVT); in neurons, CALM1 (via its long 3'-UTR isoform and FMRP-mediated axonal delivery) regulates axon elongation and neuronal migration; and as a structural cofactor in the UBR4-KCMF1-CALM1 E4 ubiquitin ligase complex, it participates in K48-linked ubiquitin chain extension for protein quality control.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll systematically classify each paper before extracting discoveries.\n\n**Classification:**\n\n- [1] KEEP - CALM1 mutation causing ventricular fibrillation, F90 mediates CaM-target interaction\n- [2] KEEP - CALM1/2/3 variants in LQTS, functional characterization of CaM-CaV1.2 interaction\n- [3] KEEP - CALM1-F142L in iPSC-CMs, CDI of ICaL mechanism\n- [4] KEEP - CALM1 promoter SNP affects transcription; CaM inhibition reduces Col2a1/Agc1 in chondrocytes\n- [5] KEEP - Chromosomal localization of CALM1/2/3\n- [6] KEEP - FMRP-miR-181d regulates axonal Calm1 translation in sensory neurons\n- [7] KEEP - Transcriptional comparison of CALM1/2/3 genes\n- [8] EXCLUDE - CAMI-1 study about CRP apheresis, alias collision\n- [9] EXCLUDE - CAMI study about cocaine myocardial infarction, alias collision\n- [10] KEEP - Calm1 RNAi causes defective precerebellar neuron migration (mouse)\n- [11] KEEP - CALM1 promoter SNP in OA (no mechanism, expression-based) — mostly association, but functional data from [4]\n- [12] KEEP (alt-locus product concern) — describes Calm1-L long 3'UTR isoform; this is an mRNA isoform study, not canonical protein. EXCLUDE as alt-locus product (alt 3'UTR isoform with distinct function)\n- [13] EXCLUDE - CaMi in pepper, plant resistance gene, symbol collision\n- [14] KEEP - CALM1 gene structure, pseudogenes, expression\n- [15] KEEP - CALM1 KO in ESCC, EMT promotion, EGFR interaction\n- [16] KEEP - CALM1 SNP association with SCD (association study, no mechanism) — EXCLUDE (no mechanism)\n- [17] KEEP - N98S Calm1 knock-in mouse, ICaL dysregulation mechanism\n- [18] EXCLUDE - neurotrophin pathway SNP association study, no mechanism\n- [19] EXCLUDE - CAMI-GUIDE study about CRP/ICD, alias collision\n- [20] EXCLUDE - association study only\n- [21] EXCLUDE - CAMI registry score, alias collision\n- [22] EXCLUDE - biomarker study, no mechanism\n- [23] EXCLUDE - association/expression study only\n- [24] KEEP - suppression-replacement gene therapy for CALM1/2/3 calmodulinopathy\n- [25] EXCLUDE - association study only\n- [26] EXCLUDE - meta-analysis of association\n- [27] EXCLUDE - microdeletion phenotype, no mechanism\n- [28] EXCLUDE - chromosomal assignment in Ateles, no functional mechanism\n- [29] EXCLUDE - meta-analysis of association\n- [30] EXCLUDE - association study only\n- [31] EXCLUDE - association study only\n- [32] KEEP - miR-205-5p targets CALM1 (luciferase assay confirmed)\n- [33] EXCLUDE - mutational spectrum report, no mechanism\n- [34] KEEP - miR-202-3p targets Calm1, NF-κB/NLRP3 signaling in ARDS\n- [35] EXCLUDE - case report\n- [36] EXCLUDE - bioinformatics/expression only\n- [37] KEEP - Erianin binds CALM1, activates CAMKK2 phosphorylation, induces autophagy\n- [38] EXCLUDE - promoter utility study, no protein mechanism\n- [39] EXCLUDE - chromosomal mapping only\n- [40] EXCLUDE - plant gene family, symbol collision (CaMi)\n- [41] EXCLUDE - association study only\n- [42] EXCLUDE - poultry/eggshell genetics, not human CALM1 mechanism\n- [43] KEEP - CALM1 splice/missense variant p.E140V causes neurological phenotype; C. elegans cmd-1 modeling\n- [44] KEEP - CALM1/2/3 expression and translation efficiency in heart\n- [45] EXCLUDE - mental illness stigma study, alias collision (CAMI)\n- [46] KEEP (preprint version of [44]) - same content as [44]\n- [47] EXCLUDE - metagenomics tool, alias collision (CAMI)\n- [48] KEEP - cryo-EM structure of UBR4-KCMF1-CALM1 complex\n- [49] EXCLUDE - immune tolerance study, CALM1 mentioned peripherally in transcriptomics\n- [50] EXCLUDE - autism/motor imitation study, CAMI = computer vision tool\n- [51] EXCLUDE - metagenomics binning, CAMI = dataset\n- [52] EXCLUDE - metagenomics misassembly, CAMI = dataset\n- [53] KEEP (preprint) - calmodulin variants in schizophrenia, functional analysis of CaV1.2 interaction\n\n**Gene2pubmed additional papers:**\n- [g1] KEEP - ExAC reference (mentions CALM1 in context of population variation) — no mechanism, EXCLUDE\n- [g2] KEEP - Cameleon Ca2+ indicators using calmodulin-M13 FRET; calmodulin wraps around M13 upon Ca2+ binding — KEEP\n- [g3] EXCLUDE - proteome-scale PPI map, CALM1 appears as a node\n- [g4] EXCLUDE - mRNA interactome, general\n- [g5] EXCLUDE - cDNA sequences\n- [g6] EXCLUDE - autophagy network\n- [g7] EXCLUDE - DUB landscape\n- [g8] EXCLUDE - quantitative interactome\n- [g9] EXCLUDE - proteome-scale interactome\n- [g10] KEEP - Crystal structure of CaM-MLCK peptide complex at 2.4 Å — foundational mechanism\n- [g11] EXCLUDE - HuRI interactome\n- [g12] EXCLUDE - TNF/NF-κB network\n- [g13] EXCLUDE - large-scale PPI by MS\n- [g14] EXCLUDE - BioPlex\n- [g15] EXCLUDE - census of protein complexes\n- [g16] EXCLUDE - GO annotation\n- [g17] KEEP - CaM binding to eNOS Thr495/Ser1177 regulation\n- [g18] EXCLUDE - ciliopathy network\n- [g19] KEEP - CaM competes with α-actinin for NR1 binding; Ca2+/CaM reduces NMDA open probability\n- [g20] KEEP - Crystal structure of SK channel CaMBD/Ca2+/CaM; N-lobe Ca2+ gating mechanism\n- [g21] KEEP - Ca2+-dependent CaM binding to NR1 reduces NMDA channel open probability 4-fold\n- [g22] EXCLUDE - centrosome-cilium BioID\n- [g23] EXCLUDE - OpenCell\n- [g24] KEEP - D1 receptor directly interacts with NR1-1a and NR2A, modulating NMDA currents (CaM-related context)\n- [g25] EXCLUDE - alternative promoters\n- [g26] EXCLUDE - cilia assembly\n- [g27] EXCLUDE - SLX4 complex\n- [g28] KEEP - Calponin inhibits actomyosin ATPase; CaM-dependent kinase II phosphorylates calponin — relevant to CaM as kinase activator\n- [g29] EXCLUDE - 14-3-3 affinity purification (CALM1 not specifically studied)\n- [g30] EXCLUDE - beta-arrestin interactome\n\nNow extracting discoveries from KEPT papers:\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1992,\n      \"finding\": \"Crystal structure of Ca2+-bound calmodulin complexed with a peptide analog of the smooth muscle myosin light chain kinase (MLCK) CaM-binding region at 2.4 Å resolution revealed that CaM forms a compact ellipsoidal tunnel that engulfs the helical target peptide; the central helix of CaM unwinds and expands into a bend between residues 73–77, allowing both hydrophobic domains to merge into a single area surrounding the peptide, with ~185 contacts formed. This established the structural basis of CaM target-peptide recognition.\",\n      \"method\": \"X-ray crystallography (2.4 Å resolution) of Ca2+/CaM–MLCK peptide complex\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution crystal structure with detailed structural validation; foundational paper with ~950 citations\",\n      \"pmids\": [\"1519061\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Ca2+-dependent binding of calmodulin to the NR1 subunit of NMDA receptors causes a ~4-fold reduction in NMDA channel open probability, establishing CaM as a direct negative regulator of NMDA receptor activity through a Ca2+-dependent feedback mechanism.\",\n      \"method\": \"Protein purification, in vitro binding assay, co-immunoprecipitation from brain, patch-clamp electrophysiology of homomeric NR1 and heteromeric NR1/NR2 complexes\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct in vitro binding plus electrophysiological functional readout, replicated in brain tissue and recombinant systems; ~465 citations\",\n      \"pmids\": [\"8625412\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Calmodulin binds to the CaM-binding domain of SK (small-conductance Ca2+-activated K+) channel α-subunits constitutively; upon Ca2+ binding exclusively to the N-lobe EF hands of CaM, channel opening is triggered. The interaction is obligatory for channel gating, placing CaM as an intrinsic subunit of SK channels.\",\n      \"method\": \"Biochemical binding assays; later (2001) crystal structure at 1.60 Å of CaMBD/Ca2+/CaM showing CaM wrapping around three α-helices from a dimeric CaMBD\",\n      \"journal\": \"Nature (structure paper 2001)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — 1.60 Å crystal structure plus biochemical data; ~500 citations\",\n      \"pmids\": [\"11323678\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"α-Actinin-2 and calmodulin compete for binding to the cytoplasmic tail of the NR1 subunit of NMDA receptors in a Ca2+-dependent manner: Ca2+/calmodulin directly antagonizes NR1–α-actinin binding, suggesting a mechanism by which Ca2+ entry through NMDA receptors can displace cytoskeletal anchoring and regulate receptor localization and activity.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation from rat brain, in vitro competition binding assay\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP from brain plus in vitro competition; ~505 citations\",\n      \"pmids\": [\"9009191\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Genetically encoded FRET-based Ca2+ indicators ('cameleons') were constructed using tandem fusions of cyan-GFP, calmodulin, the CaM-binding peptide M13, and yellow-GFP. Ca2+ binding causes CaM to wrap around M13, increasing FRET between flanking GFPs, enabling real-time measurement of free Ca2+ in cytosol, nucleus, and ER of live cells. CaM mutations were used to tune Ca2+ affinity over the range 10⁻⁸–10⁻² M.\",\n      \"method\": \"Genetic engineering, FRET imaging in live HeLa cells, calmodulin mutagenesis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution and mutagenesis with functional validation in live cells; ~2324 citations\",\n      \"pmids\": [\"9278050\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Calmodulin binding to the CaM-binding domain of eNOS is regulated by phosphorylation: constitutive phosphorylation of Thr495 (by PKC) reduces CaM binding, while agonist-induced dephosphorylation of Thr495 by PP1 promotes CaM association and enhances eNOS activity. Mutation of Thr495 to Ala increased CaM binding in unstimulated cells, while Asp495 abolished CaM binding, confirming phosphorylation as the molecular switch controlling Ca2+/CaM-dependent eNOS activation.\",\n      \"method\": \"Co-immunoprecipitation, site-directed mutagenesis, CaM binding assay, pharmacological inhibitors (Ro 31-8220, calyculin A, KN-93) in porcine aortic endothelial cells\",\n      \"journal\": \"Circulation Research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — mutagenesis plus co-IP plus pharmacological inhibition with multiple orthogonal methods; ~618 citations\",\n      \"pmids\": [\"11397791\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Chromosomal localization of the three bona fide human calmodulin genes: CALM1 maps to chromosome 14q24–q31, CALM2 to 2p21.1–p21.3, and CALM3 to 19q13.2–q13.3, establishing that these identical-protein-encoding genes are dispersed throughout the genome.\",\n      \"method\": \"PCR-based amplification from human-hamster somatic cell hybrids; in situ hybridization on human lymphocyte metaphase spreads\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — two orthogonal mapping methods; replicated in multiple studies; ~80 citations\",\n      \"pmids\": [\"8314583\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"The human CALM1 gene contains six exons spanning ~10 kb of genomic DNA with a cluster of transcription-start sites 200 bp upstream of the ATG codon. Expression is ubiquitous but differential: a 1.7 kb mRNA is uniformly present while a 4.2 kb mRNA is enriched in brain and skeletal muscle. Two intronless, non-functional pseudogenes (CALM1P1, CALM1P2) were characterized.\",\n      \"method\": \"Genomic library screening, PCR, Northern blotting, sequencing of human CALM1 gene and flanking regions\",\n      \"journal\": \"European Journal of Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct experimental characterization of gene structure and expression; ~32 citations\",\n      \"pmids\": [\"7925473\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Comparison of transcriptional activity of CALM1, CALM2, and CALM3 in proliferating human teratoma cells revealed that CALM3 is at least 5-fold more actively transcribed than CALM1 or CALM2. The 5' untranslated regions of each CALM gene are necessary to recover full promoter activity in transfection assays, indicating post-transcriptional regulation of calmodulin levels.\",\n      \"method\": \"Nuclear run-on transcription assay, Northern blotting for mRNA abundance, luciferase reporter transfection with CALM promoter constructs ± 5'UTR in teratoma cells\",\n      \"journal\": \"Cell Calcium\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods (run-on, mRNA quantification, reporter assays) in a single study\",\n      \"pmids\": [\"9681195\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"A functional SNP (−16C>T) in the core promoter of CALM1 decreases CALM1 transcription in vitro and in vivo. Inhibition of calmodulin in chondrogenic cells reduced expression of major cartilage matrix genes Col2a1 and Agc1, implicating the CALM1-mediated signaling pathway in chondrocyte differentiation and cartilage matrix production.\",\n      \"method\": \"Case-control association study; luciferase reporter assay for promoter activity in vitro; in vivo allele-specific transcription analysis; pharmacological calmodulin inhibition in chondrogenic cells with RT-PCR for Col2a1 and Agc1\",\n      \"journal\": \"Human Molecular Genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reporter assay plus pharmacological inhibition with downstream gene readout; single lab, moderate mechanistic depth\",\n      \"pmids\": [\"15746150\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"A missense mutation p.F90L in CALM1 encoding calmodulin was identified in a family with idiopathic ventricular fibrillation (IVF). The F90 residue is a highly conserved residue that mediates the direct interaction of CaM with target peptides, establishing that disruption of CaM–target interactions can cause life-threatening arrhythmia.\",\n      \"method\": \"Exome sequencing of affected family members; pedigree analysis; conservation analysis of F90 position\",\n      \"journal\": \"Journal of the American College of Cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — genetic identification with mechanistic inference from prior structural data; no direct functional reconstitution in this paper\",\n      \"pmids\": [\"24076290\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"RNAi-mediated knockdown of Calm1 (but not Calm2 or Calm3) in mouse precerebellar neurons caused defective tangential and radial migration, with neurons failing to reach target positions in the hindbrain. This established a gene-specific requirement for CALM1 in neuronal migration that cannot be compensated by the other calmodulin-encoding genes.\",\n      \"method\": \"Acute in vivo RNAi knockdown of individual Calm genes (shRNA), histological analysis of precerebellar neuron migration in mouse hindbrain\",\n      \"journal\": \"Development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — KD with specific phenotypic readout in vivo; gene-specific effect validated by testing all three paralogs; single lab\",\n      \"pmids\": [\"25519244\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"FMRP (Fmr1-encoded protein) associates with miR-181d, Map1b mRNA, and Calm1 mRNA in axons. FMRP mediates axonal delivery of miR-181d, which locally represses translation of Calm1 (and Map1b) in sensory neuron axons, negatively regulating axon elongation. NGF stimulation releases Calm1 mRNA from FMRP/miR-181d-repressing granules, promoting local calmodulin synthesis and axon elongation.\",\n      \"method\": \"Co-immunoprecipitation of FMRP with miR-181d/Map1b/Calm1; FMRP KO (Fmr1^I304N) and knockdown; axonal fractionation with protein quantification; miR-181d overexpression; NGF stimulation assays in primary sensory neurons\",\n      \"journal\": \"Cell Reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP, KO, and functional elongation assays with multiple orthogonal approaches; single lab\",\n      \"pmids\": [\"26711345\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CALM1 (and CALM2/3) variants causing LQTS reduce CaM affinity for Ca2+ and cause a functionally dominant loss of Ca2+-dependent inactivation (CDI) of the cardiac L-type calcium channel CaV1.2. The novel E141G-CaM variant showed an 11-fold reduction in Ca2+ binding affinity and dominant loss of CaV1.2 CDI, mild NaV1.5 late current accentuation, but no effect on RyR2-mediated Ca2+ release.\",\n      \"method\": \"Whole-exome sequencing; Ca2+ binding affinity measurements; patch-clamp electrophysiology of CaV1.2, NaV1.5 in heterologous expression; intracellular Ca2+ release assay for RyR2\",\n      \"journal\": \"Circulation: Cardiovascular Genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — biochemical Ca2+ affinity measurement plus electrophysiological characterization of multiple ion channels; multiple methods in one study\",\n      \"pmids\": [\"26969752\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"The CALM1-F142L mutation in patient-derived iPSC-CMs causes prolonged repolarization with altered rate-dependency, severe impairment of Ca2+-dependent inactivation (CDI) of ICaL (increased inward current during plateau), and failure of repolarization adaptation at high pacing rates. These effects were reversed by verapamil (ICaL blocker). The mutation did not affect IKs, INaL, or intracellular Ca2+ store stability, placing the primary arrhythmogenic defect specifically at CaV1.2 CDI.\",\n      \"method\": \"iPSC-CM generation from CALM1-F142L patient; dynamic clamp (simulated IK1); patch-clamp for ICaL CDI, IKs, INaL, If; intracellular Ca2+ imaging; action potential modeling; pharmacological rescue with verapamil\",\n      \"journal\": \"Cardiovascular Research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — human patient iPSC-CMs with multiple orthogonal electrophysiological methods, pharmacological rescue, and computational modeling\",\n      \"pmids\": [\"28158429\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Heterozygous Calm1-N98S knock-in mice exhibit sinus bradycardia, QTc prolongation, QRS widening, and catecholaminergic bidirectional ventricular tachycardia. β-Adrenergic stimulation increased peak ICaL density, slowed ICaL inactivation, left-shifted ICaL activation, and increased late ICaL significantly more in mutant than wild-type ventricular myocytes. Both reentry and focal mechanisms (EADs in His-Purkinje fibers, DADs in ventricular myocytes) contribute to arrhythmogenesis, establishing β-adrenergically induced ICaL dysregulation as the primary mechanism of the long-QT phenotype.\",\n      \"method\": \"CRISPR/Cas9 knock-in mouse generation; ECG monitoring; optical voltage mapping; patch-clamp (ICaL, action potentials); fluorescence Ca2+ imaging; microelectrode recording of His-Purkinje fibers; pharmacological β-blocker/agonist treatment\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — two independent knock-in lines, multiple orthogonal electrophysiological methods, optical mapping, and pharmacological rescue; strong mechanistic evidence\",\n      \"pmids\": [\"32929985\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"A suppression-and-replacement (SupRep) gene therapy construct containing shRNAs targeting CALM1, CALM2, and CALM3 plus a shRNA-immune CALM1 cDNA shortened pathologically prolonged APD90 in CALM1-F142L, CALM2-D130G, and CALM3-D130G iPSC-CMs, demonstrating that a single construct can treat all calmodulinopathy variants regardless of which of the three CALM genes is mutated.\",\n      \"method\": \"shRNA knockdown efficiency testing in TSA201 cells; lentiviral transfection of SupRep construct into patient-derived iPSC-CMs; voltage-sensing dye measurement of APD90\",\n      \"journal\": \"Circulation: Arrhythmia and Electrophysiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional rescue in human iPSC-CMs with quantitative APD90 readout; proof-of-principle single study\",\n      \"pmids\": [\"39069900\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Cryo-EM structure of the UBR4–KCMF1–CALM1 complex (~1.3 MDa ring) revealed that CALM1 (calmodulin) is a structural cofactor of the UBR4 E4 ubiquitin ligase megacomplex, which extends K48-specific ubiquitin chains on substrate proteins. The architecture is conserved across eukaryotes with species-specific adaptations, and efficient substrate targeting requires both pre-ubiquitination and specific N-degrons with KCMF1 acting as substrate filter.\",\n      \"method\": \"Cryo-EM structural analysis; biochemical reconstitution; ubiquitination assays\",\n      \"journal\": \"bioRxiv (preprint)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — cryo-EM structure with biochemical validation; preprint, not yet peer-reviewed\",\n      \"pmids\": [\"bio_10.1101_2024.12.18.629163\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"miR-202-3p directly targets Calm1 (validated by luciferase reporter assay) and suppresses Calm1 protein expression in murine lung tissue. In an LPS-induced ARDS mouse model, miR-202-3p overexpression reduced CALM1 protein levels, inactivated NF-κB/NLRP3 signaling, and attenuated pulmonary inflammation and edema, placing CALM1 upstream of the NF-κB/NLRP3 pathway in inflammatory lung injury.\",\n      \"method\": \"Luciferase reporter assay; Western blotting; immunohistochemistry; miR-202-3p agomir administration in C57BL/6 mice; LPS-induced ARDS model; measurement of NF-κB/NLRP3 signaling proteins\",\n      \"journal\": \"Cell Biochemistry and Biophysics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — validated miRNA-target interaction plus in vivo functional assay with signaling pathway readout; single lab\",\n      \"pmids\": [\"38635101\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Erianin (a natural compound) directly binds to CALM1 protein, enhancing its stability and subsequently increasing CAMKK2 phosphorylation. This CALM1/CAMKK2 axis activation promotes autophagy in 5-FU-resistant colorectal cancer cells, leading to tumor cell death and restored sensitivity to 5-FU.\",\n      \"method\": \"Drug-target binding assay; Western blotting for CALM1 stability and CAMKK2 phosphorylation; autophagy marker immunofluorescence; CCK8/EdU/Transwell proliferation and invasion assays; xenograft tumor model\",\n      \"journal\": \"Chemico-Biological Interactions\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — direct binding assay plus downstream signaling and in vivo xenograft; single lab, limited mechanistic depth on binding site\",\n      \"pmids\": [\"40976489\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"miR-205-5p promotes proliferation, migration, and invasion of nasopharyngeal carcinoma cells by directly targeting and suppressing CALM1 expression, validated by dual luciferase reporter assay. Inhibition of CALM1 by miR-205-5p mediates its oncogenic effects in NPC cells.\",\n      \"method\": \"Dual luciferase reporter assay; MTT, colony formation, Transwell assays; qRT-PCR and Western blot; overexpression in NPC cell lines\",\n      \"journal\": \"Critical Reviews in Immunology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — luciferase validation of miRNA-target plus cell assays; no defined molecular mechanism downstream of CALM1 suppression; single lab\",\n      \"pmids\": [\"39976516\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"CALM1/2 de novo variant c.419A>T (p.E140V) causes a neurological phenotype (hypotonia, motor delay, intellectual disability, abnormal EEG) without cardiac arrhythmia. RNA-seq showed the variant allele predominantly produces frameshifted C-terminal truncations via splice donor gain/intron retention (without NMD), with only a minority producing p.E140V missense protein. C. elegans cmd-1 modeling showed E140V has qualitatively and quantitatively different phenotypes from the arrhythmia variant E141G, indicating distinct molecular mechanisms for cardiac vs. neurological calmodulinopathy.\",\n      \"method\": \"Next-generation sequencing; RNA-seq of patient blood (splice analysis); C. elegans cmd-1 genetic modeling with phenotypic comparison of E140V vs. E141G\",\n      \"journal\": \"Human Molecular Genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — RNA-seq of patient tissue plus ortholog genetic modeling; mechanistic inference from combined data; two patients with same variant\",\n      \"pmids\": [\"41467504\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"Ribosome profiling of human left ventricle tissue revealed that CALM1 and CALM2 each contribute ~44–45% of total cardiac calmodulin protein, while CALM3 contributes only ~11%, despite CALM3 being more actively transcribed than CALM2 relative to protein output in some tissues. This differential translation efficiency explains why CALM3 missense variants are clinically less severe and subject to weaker negative selection (observed/expected ratio 0.29 vs. 0.11 for CALM1) than CALM1 variants.\",\n      \"method\": \"Ribosome profiling of left ventricle tissue (GTEx); RNA-seq from 49 tissues; gnomAD variant analysis; International Calmodulinopathy Registry clinical data\",\n      \"journal\": \"Europace\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ribosome profiling provides direct translational efficiency measurement; supported by population-scale variant data and clinical registry\",\n      \"pmids\": [\"41846582\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Calmodulin missense variants in schizophrenia patients fall into two functional classes: (1) loss-of-function variants reducing Ca2+ affinity and impairing CaV1.2 gating (similar to but with smaller effect than LQTS variants), and (2) gain-of-function variants unexpectedly enhancing Ca2+ affinity with no impact on CaV1.2 gating. All schizophrenia-associated variants clustered in the C-terminal lobe of calmodulin.\",\n      \"method\": \"Large-scale sequencing (24,248 schizophrenia patients, 97,322 controls); Ca2+ affinity measurements; electrophysiological characterization of CaV1.2 gating\",\n      \"journal\": \"bioRxiv (preprint)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 — biochemical Ca2+ affinity plus electrophysiology; preprint, statistical association modest (OR 5.62, P=0.043)\",\n      \"pmids\": [\"bio_10.1101_2024.05.22.24307674\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"CALM1 encodes calmodulin, a ubiquitous Ca2+ sensor that, upon Ca2+ binding, undergoes conformational change (unwinding of its central helix) to engulf target peptides in a hydrophobic tunnel, thereby activating targets including MLCK, SK channels (via N-lobe Ca2+ binding), eNOS (regulated by competitive phosphorylation of Thr495), and inhibiting NMDA receptors (via NR1 subunit binding reducing channel open probability ~4-fold); pathogenic CALM1 missense mutations (e.g. F142L, N98S, F90L) specifically impair Ca2+-dependent inactivation of cardiac CaV1.2 (L-type Ca2+ channel), leading to arrhythmias (long QT syndrome, ventricular fibrillation) through β-adrenergically exacerbated ICaL dysregulation, while CALM1 also functions as a structural subunit of the UBR4 E4 ubiquitin ligase complex, contributes ~45% of total cardiac calmodulin protein (the dominant source alongside CALM2), regulates axon elongation through local mRNA translation controlled by FMRP/miR-181d, drives precerebellar neuron migration in a gene-specific manner, and modulates NF-κB/NLRP3 inflammatory signaling.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CALM1 encodes one of three non-allelic human genes that produce identical calmodulin protein, yet it is the dominant contributor (~45%) to total calmodulin in the human heart and has non-redundant roles in neuronal development [PMID:41846582, PMID:25519244]. As a Ca²⁺ sensor, calmodulin directly mediates Ca²⁺-dependent inactivation (CDI) of the CaV1.2 L-type calcium channel; pathogenic CALM1 missense mutations reduce Ca²⁺-binding affinity and impair CDI, prolonging cardiac action potential repolarization and causing long QT syndrome, catecholaminergic ventricular tachycardia, and idiopathic ventricular fibrillation [PMID:26969752, PMID:28158429, PMID:32929985, PMID:24076290]. In neurons, the long 3′-UTR isoform of Calm1 mRNA is subject to FMRP/miR-181d-mediated translational repression and axonal delivery, and its loss disrupts dorsal root ganglion migration and experience-dependent hippocampal activation, establishing an isoform-specific role distinct from the other calmodulin genes [PMID:26711345, PMID:32522888, PMID:25519244]. CALM1 also functions as a structural cofactor in the UBR4–KCMF1–CALM1 E4 ubiquitin ligase complex, contributing to K48-linked ubiquitin chain extension for protein quality control, and signals upstream of CAMKK2 phosphorylation to regulate autophagy [PMID:40976489].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Establishing that the three human calmodulin genes reside on separate chromosomes resolved whether calmodulin gene copies were allelic or dispersed paralogs, setting the stage for gene-specific functional studies.\",\n      \"evidence\": \"PCR from somatic cell hybrids and FISH on human metaphase chromosomes\",\n      \"pmids\": [\"8314583\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Protein-level contributions of each gene not determined\", \"No functional distinction between the three genes demonstrated\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Characterizing the CALM1 gene structure (6 exons, ~10 kb) and showing tissue-differential expression of its two mRNA isoforms (1.7 kb ubiquitous; 4.2 kb brain/muscle-enriched) established that a single calmodulin gene produces functionally distinct transcripts.\",\n      \"evidence\": \"Genomic library screening, exon-intron sequencing, Northern blots across multiple tissues\",\n      \"pmids\": [\"7925473\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional significance of the two mRNA isoforms not tested\", \"Protein output from each isoform not quantified\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Demonstrating that CALM3 is transcribed at least 5-fold more than CALM1 in proliferating cells, with 5′ UTR elements required for full promoter activity, established that calmodulin genes are differentially regulated despite encoding identical protein.\",\n      \"evidence\": \"Run-on transcription, mRNA quantification, luciferase promoter-reporter assays in teratoma cells\",\n      \"pmids\": [\"9681195\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcription factor identity for differential regulation unknown\", \"Whether differential transcription holds across tissues not systematically tested\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identifying a functional CALM1 promoter SNP (−16C>T) that reduces transcription and showing that calmodulin inhibition suppresses chondrogenic gene expression placed CALM1 upstream of cartilage matrix regulation.\",\n      \"evidence\": \"Luciferase reporter, allele-specific transcription, CaM inhibition with RT-PCR for Col2a1/Agc1 in chondrogenic cells\",\n      \"pmids\": [\"15746150\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct CaM targets in chondrogenic signaling not identified\", \"In vivo cartilage phenotype of the SNP not demonstrated\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"The discovery that a CALM1 F90L missense mutation causes familial idiopathic ventricular fibrillation was the first genetic link between a calmodulin gene variant and cardiac arrhythmia, opening the field of calmodulinopathy.\",\n      \"evidence\": \"Exome sequencing of an affected family with structural inference from known CaM–target interfaces\",\n      \"pmids\": [\"24076290\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single family study\", \"No direct electrophysiological characterization of F90L effect on ion channels in this study\", \"Mechanism of arrhythmia (CDI loss vs. other) not resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Gene-specific knockdown showed that Calm1 — but not Calm2 or Calm3 — is required for precerebellar neuron migration, establishing a non-redundant developmental function despite identical protein sequence.\",\n      \"evidence\": \"In vivo RNAi of individual Calm genes in mouse embryos with histological analysis of neuronal positioning\",\n      \"pmids\": [\"25519244\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of non-redundancy (mRNA localization, expression level, timing) not resolved\", \"Whether the 3′-UTR long isoform mediates this specificity was unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showing that FMRP delivers Calm1 mRNA to axons where miR-181d represses its translation, with NGF releasing repression, identified the post-transcriptional mechanism underlying Calm1's local axonal function.\",\n      \"evidence\": \"Co-IP of FMRP with miR-181d/Calm1 mRNA, subcellular fractionation, Fmr1 KO/KD, NGF stimulation in primary sensory neurons\",\n      \"pmids\": [\"26711345\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this mechanism operates in CNS neurons in vivo not shown\", \"Downstream CaM targets in axon elongation not identified\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrating that calmodulinopathy variants (e.g., E141G) reduce Ca²⁺-binding affinity and specifically impair CaV1.2 CDI — without affecting RyR2 — pinpointed the primary arrhythmogenic mechanism for LQTS-causing calmodulin mutations.\",\n      \"evidence\": \"Fluorescence Ca²⁺-binding assay, CaV1.2 and NaV1.5 patch-clamp, RyR2 Ca²⁺ release measurement in heterologous cells\",\n      \"pmids\": [\"26969752\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Heterologous system may not recapitulate native cardiomyocyte stoichiometry\", \"Contribution of NaV1.5 late current accentuation to arrhythmia severity not quantified\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Patient iPSC-derived cardiomyocytes carrying CALM1-F142L confirmed that impaired CaV1.2 CDI is sufficient to prolong action potential repolarization in human cardiomyocytes, and verapamil rescue validated ICaL as the therapeutic target.\",\n      \"evidence\": \"iPSC-CM patch-clamp (ICaL CDI, IKs, INaL), dynamic clamp, Ca²⁺ imaging, verapamil rescue\",\n      \"pmids\": [\"28158429\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Single mutation studied\", \"Long-term efficacy and safety of verapamil in calmodulinopathy patients not established\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"CRISPR deletion of the Calm1 distal poly(A) site showed that the long 3′-UTR isoform has specific functions in DRG migration and experience-dependent neuronal activation, resolving why Calm1 has non-redundant neural roles despite encoding identical protein.\",\n      \"evidence\": \"CRISPR knock-in mouse eliminating Calm1-L isoform, smFISH, DRG histology, immediate early gene activation in hippocampus\",\n      \"pmids\": [\"32522888\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which RNA-binding proteins or localization signals in the long 3′-UTR mediate the effect not fully mapped\", \"Whether Calm1-L contributes to cardiac function not tested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"A heterozygous Calm1-N98S knock-in mouse recapitulated the full spectrum of calmodulinopathy (bradycardia, QTc prolongation, catecholaminergic VT) and revealed that β-adrenergic stimulation amplifies arrhythmogenesis through enhanced late ICaL and both early and delayed afterdepolarizations.\",\n      \"evidence\": \"CRISPR knock-in mice (two independent lines), ECG, optical mapping, patch-clamp, Ca²⁺ imaging, microelectrode recording, isoproterenol challenge\",\n      \"pmids\": [\"32929985\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CaV1.2-independent mechanisms contribute to CPVT phenotype not excluded\", \"Purkinje-specific vs. ventricular myocyte contribution not quantified in vivo\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"A suppression-replacement gene therapy simultaneously knocking down all three CALM genes and replacing with wild-type CALM1 cDNA rescued prolonged APD in iPSC-CMs from CALM1, CALM2, and CALM3 calmodulinopathy patients, establishing a unified therapeutic strategy.\",\n      \"evidence\": \"shRNA knockdown of CALM1/2/3, shRNA-immune CALM1 replacement via AAV, APD90 measurement in patient iPSC-CMs\",\n      \"pmids\": [\"39069900\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo efficacy and safety in animal models not yet reported\", \"Long-term expression stability of AAV-delivered construct unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Ribosome profiling quantified CALM1 as the dominant calmodulin producer (~45%) in human left ventricle, and population constraint analysis combined with clinical registry data explained why CALM1 mutations cause the most severe cardiac phenotypes.\",\n      \"evidence\": \"GTEx RNA-seq, ribosome profiling of left ventricle, gnomAD constraint metrics, International Calmodulinopathy Registry\",\n      \"pmids\": [\"41846582\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether protein-level dominance holds across all cardiac regions not tested\", \"Post-translational regulation of individual CALM gene products not addressed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Several major mechanistic questions remain: the structural basis for CALM1's non-redundant neuronal functions beyond 3′-UTR identity; the full catalog of tissue-specific calmodulin interactors differentially affected by calmodulinopathy mutations; and whether CALM1's role in the UBR4–KCMF1 ubiquitin ligase complex has physiological consequences in vivo.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo relevance of UBR4–KCMF1–CALM1 complex not established\", \"Tissue-specific interactome of calmodulin from each CALM gene not mapped\", \"Whether 3′-UTR-mediated localization affects cardiac function is untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [1, 2, 7, 11]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [1, 11]},\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [8]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [1, 2, 10]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 2, 7, 10, 11]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [5, 6]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [8]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [10]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [5, 6]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 1, 2, 7, 9]}\n    ],\n    \"complexes\": [\n      \"UBR4-KCMF1-CALM1 E4 ubiquitin ligase\"\n    ],\n    \"partners\": [\n      \"CACNA1C\",\n      \"SCN5A\",\n      \"UBR4\",\n      \"KCMF1\",\n      \"FMRP\",\n      \"CAMKK2\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"CALM1 encodes calmodulin-1, one of three genes producing the identical 149-residue Ca²⁺-sensing protein calmodulin, which transduces intracellular calcium signals by undergoing a conformational change—unwinding its central helix to form a hydrophobic tunnel that engulfs target peptides—thereby activating or inhibiting diverse effectors including smooth muscle MLCK, SK potassium channels (gated by N-lobe Ca²⁺ binding), eNOS (regulated by PKC-mediated Thr495 phosphorylation), and NMDA receptors (where Ca²⁺/CaM binding to NR1 reduces channel open probability ~4-fold) [PMID:1519061, PMID:8625412, PMID:11323678, PMID:11397791]. CALM1 contributes approximately 45% of total cardiac calmodulin protein and is the dominant translational source alongside CALM2; missense mutations (e.g., F142L, N98S, F90L) that reduce Ca²⁺ affinity cause dominant impairment of Ca²⁺-dependent inactivation of the cardiac L-type calcium channel CaV1.2, producing long QT syndrome and catecholaminergic ventricular arrhythmias exacerbated by β-adrenergic stimulation [PMID:41846582, PMID:32929985, PMID:28158429, PMID:26969752]. Beyond the heart, CALM1 has gene-specific roles in precerebellar neuron migration not compensated by CALM2/3, and its axonal translation is locally controlled by an FMRP/miR-181d repression complex that is relieved by NGF to promote axon elongation [PMID:25519244, PMID:26711345]. A de novo CALM1 variant (p.E140V) causes a neurological phenotype (hypotonia, intellectual disability) without cardiac arrhythmia, through aberrant splicing producing C-terminally truncated calmodulin, establishing genotype-specific mechanisms for cardiac versus neurological calmodulinopathy [PMID:41467504].\",\n  \"teleology\": [\n    {\n      \"year\": 1992,\n      \"claim\": \"The structural basis of calmodulin target recognition was established: Ca²⁺-bound CaM unwinds its central helix and wraps both lobes around a helical target peptide in a hydrophobic tunnel, explaining how a single sensor activates structurally diverse targets.\",\n      \"evidence\": \"2.4 Å X-ray crystal structure of Ca²⁺/CaM–MLCK peptide complex\",\n      \"pmids\": [\"1519061\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure captured a single target peptide; the mechanism of selectivity among hundreds of CaM targets was not resolved\", \"Dynamics of the central helix unwinding in solution remained unknown\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Genomic organization of the three human calmodulin genes was defined, mapping CALM1 to 14q24–q31 and showing that all three genes encode identical protein yet are dispersed across different chromosomes, raising the question of why three genes are maintained.\",\n      \"evidence\": \"PCR from somatic cell hybrids plus chromosomal in situ hybridization; Northern blot and promoter analysis of CALM1 gene structure\",\n      \"pmids\": [\"8314583\", \"7925473\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative protein contributions of each CALM gene to total calmodulin were unknown\", \"Functional redundancy versus gene-specific requirements not tested\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"CaM was identified as a direct Ca²⁺-dependent negative regulator of NMDA receptors, binding the NR1 subunit to reduce channel open probability ~4-fold and competing with the cytoskeletal anchor α-actinin-2 for the same NR1 binding site, establishing a feedback mechanism linking Ca²⁺ influx to receptor inactivation and cytoskeletal detachment.\",\n      \"evidence\": \"Patch-clamp electrophysiology of NR1/NR2 channels; co-immunoprecipitation from brain; in vitro competition binding with α-actinin-2\",\n      \"pmids\": [\"8625412\", \"9009191\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo significance of CaM–NR1 feedback for synaptic plasticity not demonstrated\", \"Whether CALM1-specific mRNA regulation affects this process was unknown\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"CaM was shown to function as a constitutive, integral subunit of SK channels, with Ca²⁺ binding exclusively to the N-lobe EF hands triggering channel gating—the first demonstration that CaM acts as a permanent channel subunit rather than a transient activator.\",\n      \"evidence\": \"Biochemical binding assays; 1.60 Å crystal structure of CaMBD–Ca²⁺–CaM complex (2001)\",\n      \"pmids\": [\"11323678\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CaM lobe-specificity generalizes to other channel targets was unclear\", \"Isoform-specific contributions of CALM1/2/3 to SK channel CaM pools not addressed\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"The molecular switch controlling Ca²⁺/CaM-dependent eNOS activation was identified: constitutive PKC phosphorylation of Thr495 blocks CaM binding, while agonist-induced PP1 dephosphorylation permits CaM association and enzyme activation.\",\n      \"evidence\": \"Site-directed mutagenesis of Thr495, co-immunoprecipitation, pharmacological inhibition in porcine aortic endothelial cells\",\n      \"pmids\": [\"11397791\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of how pThr495 sterically blocks CaM binding was not resolved\", \"In vivo vascular consequences of Thr495 variants not tested\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"The first causative link between a CALM1 missense mutation (F90L) and a life-threatening cardiac arrhythmia (idiopathic ventricular fibrillation) was established, demonstrating that even heterozygous disruption of CaM–target interactions is pathogenic.\",\n      \"evidence\": \"Exome sequencing and pedigree analysis of affected family\",\n      \"pmids\": [\"24076290\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No functional reconstitution of F90L effect on specific ion channels in this study\", \"Dominant-negative versus haploinsufficiency mechanism not distinguished\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Axonal CALM1 mRNA translation was shown to be locally regulated by an FMRP/miR-181d repressive complex; NGF relieves this repression, promoting local calmodulin synthesis and axon elongation—establishing a gene-specific post-transcriptional mechanism for CALM1 in neural development.\",\n      \"evidence\": \"Co-IP of FMRP with miR-181d/Calm1 mRNA; Fmr1 KO and miR-181d overexpression; axonal fractionation in primary sensory neurons\",\n      \"pmids\": [\"26711345\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether CALM2/3 mRNAs are similarly regulated by FMRP/miRNAs was not tested\", \"In vivo relevance for axon guidance phenotypes not demonstrated\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"The convergent arrhythmia mechanism of calmodulinopathy variants was defined: reduced Ca²⁺ affinity of mutant CaM causes dominant loss of Ca²⁺-dependent inactivation (CDI) of CaV1.2, with the E141G variant showing 11-fold reduced Ca²⁺ binding—while RyR2 function and NaV1.5 were only mildly affected, pinpointing CaV1.2 CDI as the primary arrhythmogenic target.\",\n      \"evidence\": \"Ca²⁺ binding affinity measurements; patch-clamp of CaV1.2, NaV1.5; RyR2 Ca²⁺ release assays in heterologous cells; patient iPSC-CM electrophysiology with verapamil rescue\",\n      \"pmids\": [\"26969752\", \"28158429\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How a single mutant allele among six CALM alleles achieves dominant-negative effect on the CaV1.2 macromolecular complex was incompletely explained\", \"Long-term remodeling effects in intact hearts not captured\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"A CRISPR knock-in mouse model (Calm1-N98S) demonstrated that β-adrenergic stimulation is the critical trigger for arrhythmogenesis: isoproterenol exacerbated ICaL density, slowed inactivation, and provoked both reentrant and focal arrhythmias (EADs, DADs), providing the first in vivo mechanistic model of calmodulinopathic LQTS.\",\n      \"evidence\": \"CRISPR/Cas9 heterozygous knock-in mice (two independent lines); ECG; optical voltage mapping; patch-clamp; Ca²⁺ imaging; His-Purkinje microelectrode recording\",\n      \"pmids\": [\"32929985\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether β-blocker therapy is sufficient to prevent sudden death long-term was not established\", \"Tissue-specific contributions of CALM1 versus CALM2/3 in the mouse heart not quantified in this study\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"A SupRep gene therapy strategy—simultaneously knocking down all three CALM genes with shRNAs and replacing with shRNA-immune CALM1 cDNA—rescued prolonged APD in patient iPSC-CMs carrying mutations in any of the three CALM genes, establishing a unified therapeutic approach for calmodulinopathies.\",\n      \"evidence\": \"Lentiviral SupRep construct in iPSC-CMs from CALM1-F142L, CALM2-D130G, CALM3-D130G patients; voltage-sensing dye APD90 measurement\",\n      \"pmids\": [\"39069900\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo delivery, long-term expression, and cardiac-specific targeting not demonstrated\", \"Potential off-target effects of triple CALM knockdown on non-cardiac tissues not assessed\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Ribosome profiling of human heart resolved the long-standing question of paralog contributions: CALM1 and CALM2 each supply ~45% of cardiac calmodulin protein while CALM3 contributes ~11%, explaining the greater clinical severity and stronger purifying selection on CALM1 variants.\",\n      \"evidence\": \"Ribosome profiling of left ventricle (GTEx); RNA-seq from 49 tissues; gnomAD constraint analysis; International Calmodulinopathy Registry\",\n      \"pmids\": [\"41846582\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether translational efficiency varies across cardiac cell types (atrial vs. ventricular vs. conduction system) is unknown\", \"Developmental dynamics of CALM paralog translation not assessed\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"A neurological calmodulinopathy phenotype distinct from cardiac arrhythmia was attributed to a CALM1 variant (E140V) that predominantly generates aberrantly spliced, C-terminally truncated calmodulin rather than the missense protein—establishing that the molecular mechanism (splice disruption vs. Ca²⁺ affinity loss) determines tissue-specific disease outcome.\",\n      \"evidence\": \"RNA-seq of patient blood showing splice donor gain/intron retention; C. elegans cmd-1 modeling comparing E140V vs. E141G phenotypes\",\n      \"pmids\": [\"41467504\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Brain-specific expression of truncated calmodulin not directly confirmed (blood RNA-seq used)\", \"How truncated CaM produces hypotonia and intellectual disability at the molecular level is unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: (1) how a single mutant CaM allele among six achieves dominant-negative effects on specific channel complexes in vivo, (2) the structural basis of CALM1 gene-specific functions in neuronal migration and axonal translation that are not compensated by CALM2/3, and (3) the physiological significance of CaM as a structural subunit of the UBR4 E4 ubiquitin ligase complex for substrate selection and protein homeostasis.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Dominant-negative mechanism at the level of CaM–CaV1.2 stoichiometry not quantitatively modeled in vivo\", \"CALM1-specific neuronal functions may reflect 3'UTR/5'UTR-mediated mRNA regulation rather than protein-level differences, but this has not been directly tested\", \"UBR4–KCMF1–CaM complex function awaits peer-reviewed validation and identification of endogenous substrates\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1, 2, 5, 13, 14, 15]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"GO:0140299\", \"supporting_discovery_ids\": [0, 2, 13]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [4, 12]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [4]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 2, 14]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 2, 5, 13, 15, 18]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [1, 3, 11, 12]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [11, 12]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [18]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [17]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [10, 13, 14, 15, 21]}\n    ],\n    \"complexes\": [\n      \"SK channel complex\",\n      \"UBR4–KCMF1–CaM E4 ligase complex\"\n    ],\n    \"partners\": [\n      \"GRIN1\",\n      \"KCNN2\",\n      \"NOS3\",\n      \"CACNA1C\",\n      \"ACTN2\",\n      \"FMRP\",\n      \"UBR4\",\n      \"KCMF1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}